Identifying Gaps Using the EPICOT+ Framework and Exploring the Association between Funding Sources and Author Conclusions in Primary Nutrition Research Addressing Non-communicable Diseases from Cochrane Nutrition Reviews: A descriptive-analytical cross-sectional study by Ruzive, Sheena
1 
Identifying Gaps Using the EPICOT+ Framework and Exploring the Association 
between Funding Sources and Author Conclusions in Primary Nutrition Research 
Addressing Non-communicable Diseases from Cochrane Nutrition Reviews: A 
descriptive-analytical cross-sectional study 
Student: Ms Sheena Ruzive  
March 2021 
Research assignment presented in partial fulfilment of the requirements for the degree of Master 
of Science (Clinical Epidemiology) in the faculty of Medicine and Health Sciences at Stellenbosch 
University 
Declaration of financial assistance: I hereby acknowledge financial assistance from Prof Lisa Bero, 
recipient of the 2015 Cochrane Anne Anderson Award, whereby a cash sum is designated by the 
recipient to assist a woman from a low-resource setting with Cochrane activities. I hereby 
acknowledge receiving a bursary from Novartis SA (Pty) Ltd, which was used to cover the cost of my 
Master of Science (Clinical Epidemiology) tuition fees. Opinions expressed and conclusions arrived 
at, are those of the authors and are not necessarily to be attributed to Cochrane or Norvatis SA 
(Pty) Ltd. 
This manuscript was drafted for submission to the BMC Research Methodology Journal 
Supervisor: Prof Celeste Naude 
Centre for Evidence-based Health Care 
Faculty of Medicine and Health Sciences, Stellenbosch University 
PO Box 241, Cape Town, 8000, South Africa 
E-mail: @sun.ac.za
2 
Co-supervisor: Ms Solange Durão 
South African Cochrane South Africa 
South African Medical Research Council 
PO Box 19070, Tygerberg 7505, South Africa       
E-mail: @mrc.ac.za
Stellenbosch University  https://scholar.sun.ac.za
3 
Declaration 
By submitting this thesis electronically, I declare that the entirety of the work contained therein is my 
own, original work, that I am the sole author thereof (save to the extent explicitly otherwise stated), that 
reproduction and publication thereof by Stellenbosch University will not infringe any third party rights and 
that I have not previously in its entirety or in part submitted it for obtaining any qualification.
Signature:  Sheena Ruzive   Date: 01 March 2021 
Stellenbosch University  https://scholar.sun.ac.za
4 
Contents 
PART A: Completed manuscript .......................................................................................................................... 7 
Abstract ............................................................................................................................................................... 9 
Background ........................................................................................................................................................ 11 
Non-communicable diseases: burden and risk factors ................................................................................. 11 
Systematic reviews as sources of evidence and to identify research gaps ................................................... 12 
Reporting conflicts of interest in Cochrane Reviews..................................................................................... 13 
Methods ............................................................................................................................................................ 16 
Aim ................................................................................................................................................................. 16 
Objectives: ................................................................................................................................................. 16 
Study Design .................................................................................................................................................. 16 
Data source .................................................................................................................................................... 17 
EPICOT+ Framework ...................................................................................................................................... 17 
Reporting of COI, funding sources and author-financial sponsor ties .......................................................... 21 
Ethical Considerations ................................................................................................................................... 25 
Results ............................................................................................................................................................... 26 
Characteristics of Included Reviews .............................................................................................................. 26 
Reporting of the “implications for research” section of Cochrane nutrition reviews according to the 
EPICOT+ framework....................................................................................................................................... 30 
Summarising research gaps in primary research based on the “implications for research” section of 
Cochrane nutrition reviews ........................................................................................................................... 31 
Implications for research for nutrition and the four major NCDs and the nutrition related risk factors . 31 
Research Gaps in nutrition and NCDs and nutrition related risk factors .................................................. 33 
Research gaps for Cancer .......................................................................................................................... 33 
Characteristics of primary studies included in Cochrane nutrition reviews addressing alternative nutrition 
supplements .................................................................................................................................................. 36 
Reporting of conflicts of interest, funding sources and author-sponsor financial ties ................................. 40 
Author conclusions .................................................................................................................................... 42 
Influence of funding source on author’s conclusions in included primary studies ....................................... 42 
Discussion .......................................................................................................................................................... 44 
Reporting of “implications for research” section according to EPICOT+ framework.................................... 44 
Summarising research gaps in primary research based on the “implications for research” section of 
Cochrane nutrition reviews ........................................................................................................................... 45 
Implications for research ........................................................................................................................... 45 
Research Gaps ........................................................................................................................................... 45 
Reporting of conflicts of interest, funding sources and author-sponsor financial ties ................................. 46 
Influence of sponsors and author-sponsor financial ties on author conclusions in included primary studies
 ....................................................................................................................................................................... 47 
Stellenbosch University  https://scholar.sun.ac.za
5 
Limitations ..................................................................................................................................................... 48 
Conclusions .................................................................................................................................................... 48 
List of Abbreviations .......................................................................................................................................... 50 
Declarations ....................................................................................................................................................... 53 
Ethics approval and consent to participate ................................................................................................... 53 
Consent for publication ................................................................................................................................. 53 
Availability of data and materials .................................................................................................................. 53 
Competing interests ...................................................................................................................................... 53 
Funding .......................................................................................................................................................... 53 
Authors' contributions ................................................................................................................................... 53 
Acknowledgements ....................................................................................................................................... 54 
Authors' information (optional) .................................................................................................................... 54 
Footnotes....................................................................................................................................................... 54 
References ......................................................................................................................................................... 55 
Additional Files .................................................................................................................................................. 72 
Table a1: Characteristics of Cochrane nutrition reviews addressing cancer............................................. 72 
Table a2: Characteristics of Cochrane nutrition reviews addressing cardiovascular diseases ................. 73 
Table a3: Characteristics of Cochrane reviews addressing chronic respiratory diseases ......................... 74 
Table a4: Characteristics of Cochrane nutrition reviews addressing diabetes ......................................... 75 
Table a5: Characteristics of Cochrane nutrition reviews addressing obesity and overweight ................. 76 
Table a6: Characteristics of Cochrane nutrition reviews addressing healthy diets .................................. 77 
Table a7: Characteristics of included primary studies included in Cochrane nutrition reviews addressing 
the four major NCDs and their nutrition related risk factors .................................................................... 78 
Table a8: Table of excluded primary studies ........................................................................................... 123 
Table a9: Research Gaps for Cochrane nutrition reviews addressing cancer ......................................... 124 
Table a10: Research Gaps for Cochrane nutrition reviews addressing cardiovascular diseases ............ 128 
Table a11: Research Gaps for Cochrane nutrition reviews addressing chronic respiratory diseases ..... 135 
Table a12: Research Gaps for Cochrane nutrition reviews addressing diabetes .................................... 139 
Table a13: Research Gaps for Cochrane nutrition reviews addressing obesity and overweight ............ 143 
Table a14: Research gaps for Cochrane nutrition reviews addressing healthy diets .............................. 147 
PART B: Appendices ........................................................................................................................................ 150 
Addendum ....................................................................................................................................................... 151 
Instruction to Authors for the BMC Medical Research Methodology Journal ............................................ 151 
Preparing main manuscript text .............................................................................................................. 151 
File formats .............................................................................................................................................. 151 
Preparing the manuscript ........................................................................................................................ 151 
Declarations ............................................................................................................................................. 153 
Stellenbosch University  https://scholar.sun.ac.za
6 
References ............................................................................................................................................... 159 
Figures, tables and additional files .......................................................................................................... 162 
Research Project Protocol ........................................................................................................................... 165 
Table of Data Extraction Domains ............................................................................................................... 185 
Acknowledgements ..................................................................................................................................... 187 
Sources of Support: ..................................................................................................................................... 187 
Anti-plagiarism software report (Turnitin) .................................................................................................. 187 
Stellenbosch University  https://scholar.sun.ac.za
7 
PART A: Completed manuscript 
Stellenbosch University  https://scholar.sun.ac.za
8 
Identifying Gaps using the EPICOT+ Framework and Exploring the Association 
between Funding Sources and Author Conclusions in Primary Nutrition Research 
Addressing Non-communicable Diseases from Cochrane Nutrition Reviews: A 
descriptive-analytical cross-sectional study 
Sheena Ruzive1, Solange Durão2, Marianne E. Visser3, Celeste E. Naude3 
1 Division of Epidemiology and Biostatistics, Department of Global Health Faculty of Medicine and Health 
Sciences Stellenbosch University, South Africa 
2 Cochrane South Africa, South African Medical Research Council, South Africa 
3 Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global 









With the rise in non-communicable diseases (NCDs) globally, we aimed to summarise the research gaps and 
describe the adequacy of the reporting of future research recommendations in Cochrane reviews of 
nutrition interventions addressing NCDs. We also aimed to explore the influence of funding sources and 
author- sponsor financial ties on author conclusions in a subset of primary studies included in these reviews. 
Methods: 
Two researchers independently screened a Cochrane nutrition reviews database (n=470, July 2015) to 
identify reviews addressing four NCDs (cardiovascular diseases, cancer, chronic respiratory diseases and 
diabetes). The “implications for research” section of eligible reviews was analysed using the evidence, 
population, intervention, comparison, outcome, timeframe, study design and burden of disease (EPICOT+) 
framework to describe the extent of reporting of research recommendations and to summarise gaps. A 
purposive sample of English full-text studies included in reviews addressing alternative nutrition 
supplements were analysed to assess reporting of conflict of interest (COI), funding sources and author-
sponsor financial ties, and to explore influences of funding sources and author-sponsor financial ties on 
author conclusions.  
Results: 
Ninety-eight eligible reviews were analysed. The EPICOT+ reporting was as follows: evidence 34/98 (33.7%), 
population 68/98 (69.4%), intervention 90/98 (91.8%), comparison 26/98 (26.5%), outcomes 78/98 (79.6%), 
study design 85/98 (86.7%), time frame 52/98 (53.1%), and burden of disease 7/98 (7.1%). Studies requiring 
better quality, different interventions, and outcomes in low- and middle-income countries (LMICs) were 
highlighted. Seven reviews addressed alternative nutrition supplements, including 51 eligible primary 
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studies. Conflicts of interest were disclosed in 10/51 (19.2%); funding in 27/51 (51.9%), of which, 11/27 
(40.7%) were industry and 16/27 (59.3%) were non-industry sponsors; and author-sponsor financial ties in 
9/51 (13.4%), of which 1/9 (11.1%) was industry and 8/9 (88.9%) were non-industry. There was no 
association between authors making favourable conclusions and having industry sponsors and author-
sponsor financial ties (8/12) compared with non-industry sponsors and no author-sponsor financial ties 
(10/24), (Fisher exact p =0.289). 
Conclusions: 
EPICOT+ items were not well reported in most reviews. Future studies of better quality, different 
interventions, outcomes or populations in LMICs are needed. Authors should disclose all COI, funding 
sources and author-sponsor financial ties. Possible influences of funding sources and author-sponsor 
financial ties on author conclusions needs further investigation. 
Keywords: Non-communicable diseases, Nutrition, Cochrane systematic reviews, Research 
recommendations, EPICOT+ Framework, Conflicts of interest, Funding  
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Background 
Non-communicable diseases: burden and risk factors 
Non-communicable Diseases (NCDs) are medical conditions that are non-infectious and not transmissible 
between people (1). Non-communicable Diseases are commonly categorised into the following groupings: 
cardiovascular diseases, cancer (all types), chronic respiratory diseases (e.g. asthma, bronchitis), diabetes 
(type 1 and 2), renal disease, endocrine disease, neurological disorders, haematological disorders (e.g. sickle 
cell anaemia), gastroenterological disease (e.g. peptic ulcers), hepatic disease (e.g. liver cirrhosis), 
musculoskeletal disorders, skin diseases, oral diseases, genetic disorders, mental disorders, optometry 
disorders and deafness (2). The four major groups that contribute to over 80% of deaths from NCDs are 
cardiovascular diseases, cancer, chronic respiratory diseases and diabetes (1). In 2018, NCDs accounted for 
41 million deaths globally (3). Annually, about 15 million people die prematurely (people between age of 30-
69) from a NCD and over 85% of these "premature" deaths occur in LMICs (3). The WHO aims to reduce
premature mortality from NCDs by one-third through prevention and treatment and it recommends that 
governments and stakeholders adopt effective interventions to halt this global rise in NCDs (2). 
Risk factors associated with NCDs largely stem from unhealthy lifestyles and exposure to adverse physical 
and social environments. Modifiable risk factors include unhealthy diets, direct and passive smoking, other 
uses of tobacco, physical inactivity, excessive use of alcohol and psychological stress (4–7). Poor nutrition 
during pregnancy and childhood also predisposes individuals to develop NCDs in adulthood (8,9). Knowledge 
of the modifiable risk factors contributing to NCDs presents an opportunity to find effective interventions to 
reduce the incidence of NCDs (4). 
 A vast body of observational and experimental evidence has shown that people with healthier diets have a 
lower risk of developing NCDs. A meta-analysis of nine cohort studies (n=91,379 men and n=129,701 
women) reported that the risk of developing coronary heart disease decreased by 4% for each additional 
portion per day of fruit and vegetable intake and decreased by 7% [RR (95%CI): 0.93 (0.89–0.96), P<0.0001] 
for fruit intake (5). Vegetable intake also reduced the risk of mortality [RR (95%CI): 0.74 (0.75–0.84), 
Stellenbosch University  https://scholar.sun.ac.za
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P<0.0001] and fatal and nonfatal myocardial infarctions [RR (95%CI): 0.95 (0.92–0.99),P<0.0058] (5). Another 
systematic review of randomised control trials (RCTs) found that reducing the consumption of dietary 
saturated fat reduced the risk of cardiovascular events by 17% [RR (95%CI) 0.83 (0.72 to 0.96)] in individuals 
regardless of whether they had a previous cardiovascular event or not (10). The evidence from these and 
other studies demonstrates the potential for lifestyle interventions, including those addressing dietary risks, 
to prevent NCDs (11–13). 
In light of the above evidence and the need to adopt interventions that are effective in halting the rise in 
NCDs globally, and especially in LMICs, the WHO proposed a Global Action Plan for the prevention and 
control of NCDs (2). This action plan highlights the need to use strategies based on the latest scientific 
evidence and/or best practice, cost-effectiveness, affordability and public health principles, while ensuring 
that recommendations are culturally acceptable (2). 
Systematic reviews as sources of evidence and to identify research gaps 
The best available evidence is commonly considered to be from rigorously conducted and reported 
systematic reviews (14). Cochrane systematic reviews are regarded as high quality sources of synthesised 
scientific evidence, as they follow robust and standardised methodology (15). Cochrane systematic reviews 
attempt to collate all empirical evidence that fits pre-specified eligibility criteria in order to answer a specific 
research question (16). 
In Cochrane reviews, authors are required to include sections about the implications for practice and 
research in light of the evidence that has been synthesised in the review; information that is used 
increasingly often by people making decisions about future research (16). The “implications for research” 
section should include information about the need for further research, as well as the desirable nature of 
this research (16). Even though the extent to which this section is completed in Cochrane reviews is variable, 
most reviews identify residual uncertainty and are a rich source of suggestions for further research (17). 
Analysing the content of the “implications for research” section of Cochrane reviews can help inform 
primary research gaps, as well as identify interventions for which the evidence is conclusive and thus do not 
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require further research (18). The problem, however, is the variability in formulating and reporting research 
recommendations by different systematic review authors (19). 
The EPICOT+ framework was developed to provide a means of standardised reporting of recommendations 
under the “implications for research” section of reviews (20). According to the EPICOT+ framework, research 
recommendations should be made in consideration of the current state of evidence (E) found by a thorough 
up to date literature search, the number of systematic reviews and primary studies being analysed and the 
total number of the participants from the reviews. Other factors to consider when making recommendations 
include the population (P) being studied (type of participants, their age, race, gender, comorbidities and 
specific inclusion criteria), the intervention (I) being tested (type, dose, frequency, duration), the comparison 
(C) (placebo, other drugs or no intervention, duration), the outcome of interest (O) and the time frame (T)
(i.e. the length of follow up of participants and duration of future primary studies). The “+” refers to the 
study design and the burden of the disease of interest, which are additional elements to be considered and 
stated clearly when formulating recommendations. Apart from allowing for the formulation of 
recommendations in a standardised manner, using the EPICOT+ framework ensures that recommendations 
for future research are specific and explicit and thus more useful (20). For any future primary research it is 
also important that it clearly reports potential authors’ funding and conflicts of interest, as previous studies 
have shown that financial ties between study authors and funders may influence how authors interpret 
study findings (21,22). 
Reporting conflicts of interest in Cochrane Reviews 
For valid interpretation and application of systematic review findings, high methodological quality is a 
prerequisite. A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2) has been developed to assess 
the methodological quality of systematic reviews , which has been tested and shown to have good 
agreement, reliability, construct validity and feasibility (23). The AMSTAR 2 tool aims to ensure that bias was 
avoided during the conduct of systematic reviews, through evaluating the methodology reported against 16 
distinct criteria (24). According to the AMSTAR 2 tool checklist, items 10 and 16 require that conflicts of 
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interest (COI) and sources of support be clearly acknowledged in the primary studies included in the review 
and the systematic review (24). Conflict of interest is defined as a set of conditions in which professional 
judgment concerning a primary interest (such as a patient’s welfare or the validity of research) tends to be 
unduly influenced by a secondary interest (such as financial gain) (25). 
Most systematic review authors report their COI and sources of funding for the review, however, a recent 
analysis found that only 21/296 (7%) reviewers reported the COI or funding sources of the primary studies 
included in their reviews (26). This has important implications since the outcome of the study and 
interpretation of study findings may be influenced by the source of funding and author-sponsor financial ties 
(22). Lesser and colleagues explored the relationship between financial sponsorship and study conclusions 
on the benefits of milk, soft drinks and juice from interventional studies, observational studies, and scientific 
reviews (27). None of the interventional studies that received industry funding reported unfavourable 
conclusions whilst 37% of the studies that did not receive industrial funding reported unfavourable 
conclusions about milk, soft drinks and juice consumption. A qualitative systematic review by Schott and 
colleagues (28), which explored the association between financing of drug trials by pharmaceutical 
companies and the drug trial outcomes found that trials reporting a favourable outcome were 7.61 times 
more likely to have received industry funding compared to the trials reporting an unfavourable outcomes. A 
study of published systematic reviews assessing the effect of sugar-sweetened beverages (SSB) consumption 
and weight gain or obesity found that the reviews that reported COI were five times more likely to present a 
conclusion of no positive association between SSB consumption and weight gain compared to reviews that 
did not report COI [RR (95%CI): 5.0 (1.3–19.3)] (29). These studies provide evidence that financial ties 
between study authors and funders may influence how authors interpret study findings. This highlights the 
need for review and primary study authors to declare their COIs and study sponsor information and 
affiliation when reporting studies. 
With the rise in NCDs globally, there is a need to identify research gaps in the primary evidence base on 
nutrition interventions that may be useful to control the NCD burden. Cochrane nutrition reviews addressing 
NCDs provide the best scientific evidence to inform further research; however, there is a need to explore 
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how review authors report recommendations and identify areas that need improvement to achieve 
standardised and more useful reporting of recommendations. Since financial ties between study authors and 
funders may influence how authors interpret study findings, there is the need to assess how primary study 
authors report their COIs, funding sources information and author-sponsor financial ties and to explore the 
influence of funding sources information and author-sponsor financial ties on author conclusions in primary 
studies included in Cochrane nutrition reviews addressing NCDs. 
  






We aimed to describe the reporting of the “implications for research” section using the EPICOT+ framework, 
to summarise research gaps identified in the “implications for research” section of Cochrane Nutrition 
Reviews addressing the four major groups of NCDs, namely cardiovascular diseases, cancer, respiratory 
disease and diabetes and their nutrition-related risk factors (e.g. obesity), as well as to assess reporting of 
COI, funding sources and author sponsor financial ties and exploring the influence of these funding sources 




(1) Describe the reporting of the “implications for research” section of Cochrane nutrition reviews 
addressing the four major groups of NCDs, namely cardiovascular diseases, cancer, respiratory disease and 
diabetes and their nutrition-related risk factors (e.g. obesity) according to the EPICOT+ framework; 
(2) Summarise current gaps in primary research based on the “implications for research” section of Cochrane 
nutrition reviews addressing the four major groups of NCDs and their nutrition-related risk factors (e.g. 
obesity); 
(3) Assess the reporting of COI and financial sponsors in included English primary studies of Cochrane 
nutrition reviews addressing alternative nutrition supplements (e.g. chitosan, cinnamon, Coenzyme Q, 
dietary flavonoid and garlic) and the four major groups of NCDs and their nutrition-related risk factors (e.g. 
obesity); and 
(4) Explore the influence of funding sources and author-sponsor financial ties on author conclusions in 
included English primary studies of Cochrane nutrition reviews addressing alternative nutrition supplements 
and the four major groups of NCDs and their nutrition-related risk factors (e.g. obesity).  
Study Design 
A descriptive analytical cross-sectional study. 
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 Data source 
The source of systematic reviews for this study was a database of Cochrane nutrition reviews compiled for a 
previous project, in which all active records in the Cochrane Database of Systematic Reviews (n=8484) up to 
31 July 2015, were screened to identify nutrition-relevant reviews using a pre-specified definition (Box 1). A 
total of n=470 completed Cochrane nutrition reviews were included in the database. 
 














EPICOT+ Framework  
 
Selection of Cochrane nutrition reviews addressing the four major non-communicable diseases and their 
nutrition-related risk factors 
A pair of researchers (SR and CEN/SD) independently screened the Cochrane nutrition reviews database 
(n=470), examining the title, and if needed the abstract and full-text to ascertain eligibility. Reviews were 
eligible if they addressed any of the four major groups of NCDs, namely cardiovascular diseases, cancer, 
chronic respiratory diseases and diabetes or their nutrition-related risk factors (e.g. obesity). Reviews were 
excluded if they were withdrawn or included pregnant women as participants since reviews addressing 
Nutrition reviews were defined as reviews that investigate the effectiveness of interventions of: 
(1) Diets and dietary patterns; foods; formulated, fortified or enriched foods or nutritional 
products and nutrients and bioactive non-nutrients naturally in foods delivered orally, enterally 
or parenterally; 
(2) Nutrition education, promotion, counselling and programmes; coordination of care or 
delivery of foods or nutrients; and  
(3) Any policies, programmes or systems that influence outcomes clearly distinguishable as 
nutrition-related (nutrition-sensitive).  
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pregnant women were beyond the scope of this project. Any disagreements on inclusion or exclusion of 
reviews were resolved by discussion and consensus among the three researchers. In cases where eligible 
reviews had been updated, the most recent updates (up to December 2020) of all the eligible reviews 
identified during the screening process were used for the analyses.  
 
Data Collection 
Data extraction for all reviews was performed by one researcher (SR) using a standardised and piloted data 
extraction form. For quality control, MV, SD and CN independently checked the data from 20% of the 
reviews. There was good agreement between authors. Discrepancies were resolved through discussion. 
 
We collected the following information from the eligible Cochrane nutrition reviews: accession number, title, 
NCD grouping, NCD being addressed and/or nutrition-related risk factor being addressed, populations and 
interventions, and publication year. We extracted the following EPICOT+ items from the ”implications for 
research” section of all included Cochrane nutrition reviews: evidence, participants, intervention, 
comparison, outcomes, timeframe of the study, study design and burden of disease. If an EPICOT+ item was 
explicitly stated and/or explained in the “implications for research” section, we coded the item as “TRUE”. 
For example, we recorded TRUE for “population” for the recommendation: “More randomised trials are 
needed on the effects of vitamin D on cancer in younger persons, in men, and in people with low vitamin D 
status” (29). Table 1 shows examples for the coding for each EPICOT+ Framework item. If the element was 
not stated and/or explained in the “implications for research” section, we coded it as “FALSE” in the data 
extraction sheet. We also copied and pasted the text from the “implications for research” section to the data 
extraction sheet to justify the TRUE/FALSE judgements. We extracted data from the text of the “implications 
for research” section from each included nutrition review to i) Summarise and categorise this data into 
implications for research themes that will guide future research, and to 
ii) Identify the specific EPICOT+ framework components of the recommendations for future research, e.g., 
the specific age or gender of participants or study design future research should address. 




Table 1: Examples of EPICOT+ framework implications for research coding  
EPICOT+ Framework item Example of “implications for research section” EPICOT+ items coded as “TRUE” 
(reference) 
Evidence Given the small number of studies that have been conducted to date, there is need for 
research in this area. Only two studies have been conducted to date in children so it is 
difficult to make any firm conclusions as to the benefits, or otherwise, of marine n-3 
fatty acid supplementation in this age group(30) 
Population More randomised trials are needed on the effects of vitamin D on cancer in younger 
persons, in men, and in people with low vitamin D status(31) 
Intervention The intervention should be designed to study pure compounds and compare outcomes 
with a placebo group(32) 
Comparison Future studies should ensure that innovative interventions are always compared to 
’standard care(33) 
Outcome Further trials should measure important outcomes which include mortality, morbidity 
and quality of life.(34) 
Timeframe High quality trials with follow-up for one year or more are notably sparse(35) 
Study design International, multicentre, rigorously designed, adequately powered, long-term, high-
quality studies are required to provide better evidence(36) 
Burden of disease We urge researchers and funding bodies in all countries to support research on 
childhood obesity in low- and middle-income countries, and better understand the 
experiences of nutrition transition and rapid weight gain. In the context of some 







We used descriptive statistics and data are presented as counts and percentages, and visually, using graphs 
and tables.  




We classified the included reviews according to the NCD grouping addressed (cardiovascular diseases, 
cancer, chronic respiratory disease, diabetes and nutritional risk factor -obesity and healthy diets) and 
reported these data as counts and percentages. We tabulated the characteristics of the reviews. We 
reported the percentages of reviews making recommendations according to the EPICOT+ framework 
elements, for example, the total number of reviews that made recommendations considering the population 
(total number of “TRUE” for population) is expressed as a percentage of the total number of reviews 
included in this analysis. We also describe which EPICOT+ framework elements were better or less well 
reported in these reviews.  
 
Implications for research  
We summarised the research recommendations extracted from the “implications for research” sections of 
the reviews into categories of future research themes as shown in Box 2.  
For each NCD grouping and nutritional risk factor, we presented the number of reviews highlighting a future 
research theme (e.g. the number of reviews that recommended studies with better quality for the NCD 
grouping cancer). We presented these data in graphs for each NCD grouping and nutrition-related risk 
factor. 
 
Summarising Research Gaps 
We also identified research gaps from “implications for research” section text and summarised the key 
specific EPICOT+ Framework components (with exceptions to the evidence and burden of disease) for which 
future research should address: population (e.g. gender, age, disease stage), interventions (specific 
intervention components, modality of intervention administration), comparison (e.g. placebo, standard care 
or other treatment), outcomes (e.g. adverse events, efficacy, mortality), study design (e.g. RCTs, systematic 
reviews, quality of study, adherence to guidelines) and time frame (duration of study, length of follow up). 
We presented these research gaps in tables for each NCD grouping and nutrition-related risk factor. 
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Box 2: Categories of future research themes for Implications for research 
 no more trials required, 
 more trials required overall,  
 more studies with better quality required,  
 more studies in a different setting required, 
  more studies in a different population required,  
 more studies with different interventions required, 
  more studies with different outcomes required, 
  more studies with longer duration of follow up required,  
 further evidence unlikely to come from trials,  
 more systematic reviews required,  
 more cohort studies required, 
 more qualitative studies required  
 More cost effectives / economic evaluation studies required.   
 
 
Reporting of COI, funding sources and author-financial sponsor ties 
 
Selection of primary studies included in Cochrane nutrition reviews addressing alternative nutrition 
supplements.  
From the eligible Cochrane nutrition reviews addressing the four major groups of NCDs and their nutrition 
related risk factors, we identified and selected reviews addressing alternative nutrition supplements. We 
selected studies on alternative nutrition supplements since they are likely to be funded by the 
manufacturers of such supplements, as demonstrated by the findings of a review assessing the effectives of 
Pine bark (Pinus spp.) extract for treating chronic disorders, in which Horphag Research, the manufacturer 
and holder of the Pycnogenol® registered trademark (Pine bark (Pinus spp.) extract), funded nine of the 
studies included in this review (38). We defined an alternative nutrition supplement as a supplement not 
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containing macronutrients or micronutrients but any alternative bioactive substance(s) (e.g. chitosan, 
cinnamon, coenzyme Q, garlic, isoflavones and creatine). We then extracted the citations of the included 
primary studies from the reference list of each eligible review and obtained the full-texts of these primary 
studies. We included full-text primary studies and theses by students and excluded abstracts, as well as 
primary studies in a language other than English. If there was more than one reference for the same study in 
a review, the most recent reference for that study was selected.  
Data Collection 
Data extraction for all primary studies was performed by one researcher (SR) using a standardised and 
piloted data extraction form. For quality control, MV, SD and CN independently checked the data from 20% 
of the primary studies. There was good agreement between authors. Discrepancies were resolved through 
discussion. 
 
Primary studies and funding 
We analysed the full-texts of English primary studies included in the selected Cochrane nutrition reviews 
addressing the four major NCDs and alternative nutrition supplements. We extracted the declaration of COI, 
disclosure of funding sources, type of funding sources, disclosure of author-sponsor financial ties and the 
types of author-sponsor financial ties. Declaration of COI, disclosure of funding sources and disclosure of 
author-sponsor financial ties were extracted from the declaration of sources of support or acknowledgments 
or footnotes in the article or supplementary material. Disclosed funding sources and author-sponsor 
financial ties were categorised as shown in Box 3 and Box 4, respectively. We also extracted author’s 
conclusions about the effectiveness of the alternative supplement from the abstract and discussion section 
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Funding sources were categorised as follows: 
Industry Sponsors 
 Food industry (Big food, food industry-primary producer, food processing industry, wholesale 
and retail industry and catering industry);  
 
 Pharmaceutical industry (Pharmaceutical and/or medical device industry), 
 
 Mixed funding sources with food industry (Multiple funding sources for a project that include 
food industry e.g. a study sponsored by Big food and a governmental agency); 
 
 Mixed funding sources with pharmaceutical industry (Multiple funding sources that include 
pharmaceutical industry e.g. a study sponsored by pharmaceutical industry and an academic 
institution); 
 
 Mixed funding sources with food and pharmaceutical (multiple funding sources that include 




 Governmental funding (Governmental agencies or structures and or inter-governmental 
agencies only); 
 
 Nonprofit (Academic institutions, university affiliated research centres, non-university research 
institutes / research bodies, professional associations and / or non-profit entities  non-industry, 
or both);  
 
 Other for profit entities (Trade associations , national and international business associations 
and or peak bodies);  
 
 Mixed funding sources without industry (Multiple funding sources but none belongs to food 
Industry or pharmaceutical industry e.g. a study is funded by an academic institution and a 
governmental agency). 
 





























We used descriptive statistics and data are presented as counts and percentages, and visually, using tables. 
We calculated the Fischer exact test with a significance of p< 0.05, to explore the influence of funding 
sources and author-sponsor financial ties on author conclusions for included primary studies. 
 
Author-financial sponsors were defined as authors 
 being a current or former industry consultant,  
 being a current or former industry board members, 
 being a current or former industry employees,  
 receiving industry grants, 
 receiving non-industry grants,  
 receiving royalties, 
 receiving travel reimbursement,  
 receiving payment for lectures,  
 receiving payment for manuscript preparation,  
 receiving payment for education, 
 having stocks in industry, 
 having other relationships with industry,  
 holding patents (planned, pending, or issued)  
 Providing expert testimony. 
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Reporting of COI, funding sources and author-sponsor financial ties 
The following data from included primary studies were presented as counts and percentages of the total 
number of included primary studies: reporting of conflict of interest (number of studies that declared COI / 
total number of included primary studies), disclosure of author-financial sponsor ties (number of studies 
where authors disclosed author-sponsor financial ties/ total number of included primary studies) and type of 
study sponsor (e.g. number of studies that received funding from government/ total number of studies that 
disclosed funding sources).  
Influence of funding source and author-financial sponsor ties on author’s conclusions  
We categorised sponsors into two types: industry sponsors (food industry, pharmaceutical industry, mixed 
funding with food, mixed funding with pharmaceutical industry , mixed funding with both industry and 
pharmaceutical industry and industry author-financial sponsor ties) and non-industry sponsors 
(governmental, non-profit, other for-profit entities, mixed funding sources without food and pharmaceutical 
industry and non-industry author-financial sponsor ties). 
Authors’ conclusions were classified as favourable or unfavourable to sponsor. Author conclusions 
favourable to sponsor was where the authors arrived at a positive conclusion regarding the experimental 
item (intervention) such that the conclusions were in favour of the sponsor. Authors’ conclusions 
unfavourable to sponsor was where the authors arrived at a negative conclusion about the experimental 
item such that the conclusions were not in favour with the sponsor. We performed the Fisher exact test at a 
significance level of p < 0.05 to establish whether sponsors (industry sponsors compared with non-industry 
sponsors) influence author conclusions. 
 
Ethical Considerations 
The samples in this research are not people, but published reviews and primary studies, thus ethics approval 
is not required.  




Characteristics of Included Reviews  
Of the 470 nutrition reviews screened, we identified 98 that addressed the four major NCDs (n=83) and their 
associated nutrition-related risk factors (n=15) (Figure 1). The reviews were categorised into the following 
NCD groupings and risk factors: cancer 15/98 (15.3 %)(31,32,39–51), chronic respiratory diseases 11/98 
(11.2%)(30,52–61), cardiovascular diseases 40/98 (40.8%)(10,12,13,35,36,62–96), diabetes 17/98 
(17.3%)(11,97–112), overweight and obesity 12/98 (12.2%)(33,34,37,113–121), healthy diets 
3/98(3.1%)(122–124). Table 2 below provides a summary of the characteristics of these reviews.  Detailed 
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Figure 1: Selection of Cochrane nutrition reviews addressing the four major NCDs and their 




























Figure 1 shows the selection of Cochrane nutrition reviews (n=98) addressing the four major NCDs (cancer, 
cardiovascular diseases, chronic respiratory diseases and diabetes) and their nutrition-related risk factors 
(obesity and overweight); and Healthy diets) and the selection of primary studies (n=51) included Cochrane 




Excluded reviews not addressing NCDs/nutrition-
related risk factors (n=372) 
 
Cochrane nutrition reviews database (n=470) 
 
Included reviews addressing the four major NCDs and their nutrition-
related risk factors (n=98) 
 
 
Reviews addressing alternative nutrition supplements (n=7) including 59 primary 
studies in total (no duplication) 
 
 
Excluded Reviews not addressing alternative 
nutrition supplements (n=91)                                                   
 




Excluded non-English primary studies                       




































Stellenbosch University  https://scholar.sun.ac.za
28 
 







Population Intervention (n=)-Years published 
Cancer  15/98 
(15.3%) 
 
Healthy people (n=3): e.g. adults ≥ 18 years (39) 
People at high risk (n=4): e.g. high risk of gastrointestinal cancer 
(31,39–41) 
People with disease (n=8): e.g.  Children and young people (ages≤ 21 
years) with malignant disease( 41–45,47,49,50) 
Consumption of specific nutrients or foods (n=6): e.g. dietary 
fibre, green tea (32,39,40,43,44,49) 
Diets and dietary patterns (n=1): e.g. low bacterial diets (47) 
Nutritional support (n=2): e.g. enteral feeding (42,45) 
Supplementation (n=6): e.g. antioxidants, Vitamin C, Vitamin 
D (31,41,46,48,50,51) 
(n=1)- 2006, 2007, 
2011, 2012, 2013, 
2014, 2015, 2018, 
2020 







Healthy people (n=6): e.g. adults ≥ 18 years without cardiovascular 
disease (69,76,82,91–93)  
People at high risk (n=13): e.g. Adults ≥18 years with essential 
hypertension at any risk (12,13,35,71–73,84,85,87,94,125) 
People with disease (n=21): e.g. Adults ≥18 years with existing 
cardiovascular disease (36,62–68,70,74,75,77–81,83,86,88–90) 
Consumption of specific food groups or foods (n=7): whole 
grain cereals, cocoa powder, green or black tea 
(36,62,82,85,87,90,94) 
Dietary patterns or dietary changes (n=15): e.g. 
Mediterranean diet 
(12,13,35,63,64,68,70,73,75,76,81,86,91,93,125) 
Supplementation (n=15): zinc, creatine, Coenzyme Q10(65–
67,72,74,77–80,83,89,92,95) 
(n=1)-1998,  2003, 
2004, 2007, 2009, 













People at high risk (n=1): e.g. Children at high risk of developing 
atopy or asthma (61)  
People with disease (n=10): e.g. Individuals with allergic asthma (e.g. 
sensitivity to aspirin or tartrazine) (30,52–56,56–58,60) 
Consumption of specific food groups or foods (n=4): e.g. 
Caffeine or coffee, selenium, tartrazine (55,58,60,61) 
Supplementation (n=3): e.g. Vitamin C (53,56,59) 
Dietary patterns or dietary changes (n=4): e.g. dietary calorie 
reduction (30,52,54,57) 
(n=1)- 2000, 2001, 
2003, 2004, 2009, 
2010, 2011, 2013, 
2014  
(n=2)- 2012 
Diabetes  17/98 
(17.3%) 
 
People at high risk (n=3): e.g. pre-diabetic individuals, or Individuals 
with insulin resistance (98,104,105) 
People with disease (n=14): e.g.  Adults with diabetic retinopathy, 
diabetic retinopathy, diabetes kidney disease, individuals with type 1 
or type 2 diabetes (11,97,99–103,106–112) 
Consumption of specific food groups or foods (n=3): e.g. 
whole grain foods cinnamon (105,108,111) 
Supplementation (n=4): e.g. vitamin C/super oxidase 
dismutase (99,104,107,112) 
Dietary patterns or dietary changes (n=8): e.g. low glycaemic 
index (GI) or low glycaemic load diet (11,97,98,100–
102,106,109) 
Nutrition education and counselling programmes (n=2): e.g. 

















People at high risk (n=1): e.g. overweight or obese  children (37) 
People with disease (n=11): e.g overweight and obese individuals 
(children and adolescents ages 0 to 18 years and adults ages≥ 18 
years) (33,34,113–121) 
Consumption of specific food groups or foods (n=2): e.g. 
Green tea; chitosan (34,116)  
Dietary patterns or dietary changes (n=5): e.g. low glycaemic 
index or low glycaemic load diet (113,117,119–121) 
Nutritional products and nutrients and bioactive non-
nutrients (n=1): Chromium picolinate (CrP)(118), 
Nutrition education and counselling programmes (n=4): e.g. 
intervention directed at the healthcare professional or 
organisation of care to help implement weight reduction 
interventions in children and adults with overweight or obesity 
(33,37,114,115) 
(n=1)-2007, 2008, 






Healthy Diets 3/98 
(3.0%) 
 
Healthy individuals (n=3): e.g. children ages≤ five years, Individuals 
ages ≤18 years, People of all ages(122–124) 
 
Consumption of specific food groups or foods (n=1): e.g. fruits 
and vegetables (123) 
Nutrition education and counselling programmes (n=1): e.g. 
dietary advice and counselling interventions (124)                                                                                 
Policy or system programmes (n=1): e.g. policy interventions 
to instigate healthy behavior change (122) 
(n=1) 2008, 2013, 
2020 
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Reporting of the “implications for research” section of Cochrane nutrition reviews 
according to the EPICOT+ framework 
Figure 2 shows the extent of reporting of EPICOT+ Framework items in the “implications for 
research” section of Cochrane nutrition reviews addressing the four major NCDs (cancer, 
cardiovascular diseases, chronic respiratory diseases and diabetes) and their nutrition-related risk 
factors (obesity and overweight and healthy diets) (n=98). The most reported EPICOT+ item was the 
intervention 90/98 (91.8%). The least reported items were the evidence and the burden of disease, 
which were reported in 34/98 (33.7%) and 7/98 (7.1 %) of the reviews, respectively. The population 
was reported in 68/98 (69.4%) of reviews, the comparison in 26/98 (26.5%), the outcome in 78/98) 
(79.6%), the study design in 85/98 (85.7%), and the time frame in 52/98 (53.1 %). No review 
reported all the EPICOT+ items.  
 
Figure 2: Percentages of included Cochrane nutrition reviews (n=98) that reported elements of the 
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Summarising research gaps in primary research based on the “implications for 
research” section of Cochrane nutrition reviews 
Implications for research for nutrition and the four major NCDs and the nutrition related risk 
factors 
Figure 3 shows the future research recommendation themes extracted from the “implications for 
research” section of eligible Cochrane nutrition reviews for each NCD grouping and nutrition-related 
risk factor. Reviews in all the NCD groupings highlighted the need for more trials overall, more 
studies in a different population, more studies with different interventions and outcomes, more 
studies with larger samples and more studies with better quality. Lesser highlighted themes were 
more trials with a different comparison, more trials with longer follow up and more economic 
evaluation studies. Future research with study designs other than trials were highlighted in a few 
NCD groupings; more cohort studies (cancer and obesity and overweight), more systematic reviews 
(obesity and overweight) and more qualitative studies (cardiovascular diseases and obesity and 
overweight). In the chronic respiratory review, “caffeine for asthma”, caffeine was found to have 
bronchodilatory effects. However, no more trials are required in the future since caffeine is not 
recognised as a treatment for asthma.  
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Figure 3: Implications for research for Cochrane nutrition reviews addressing the four major NCDs and their nutrition related risk factors 
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Research Gaps in nutrition and NCDs and nutrition related risk factors 
We provide a brief summary of research gaps for each NCD grouping below. The detailed summary 
of the research gaps for each NCD grouping are presented in Additional Files (Section 8, Tables a9 to 
a14).  
Research gaps for Cancer 
Future studies should include homogenous study populations in terms of anticancer treatment and 
disease stage (47), people at high risk of cancer (e.g. younger persons, men, and in people with low 
vitamin D status) (31)and specific ethnic groups e.g. groups other than the Chinese population (44), 
as well as individuals with cancer (e.g. head and neck cancer(42), children with high-risk 
neuroblastoma (41)). Recommended interventions include foods containing dietary flavonoids (32) 
or calcium (39), consumption of green tea (40) or supplements (e.g. lycopene (51), selenium (50)). 
Outcomes recommended included survival (41,43,44), cancer diagnosis (e.g. liver cancer and 
melanoma) (46,51), quality of life (31,41), risk-benefit balance (39), safety (45) and adverse events 
(41,51). RCTs should adopt standard reporting guidelines.(e.g. SPIRIT; CONSORT) when planning, 
executing and reporting trials (31,43,44,126,127). 
Research Gaps for cardiovascular  
Future studies should include individuals with a high risk of cardiovascular diseases (e.g. populations 
with low calcium intake, elderly stroke patients), individuals with cardiovascular diseases (e.g.  
Hypertension (90) (77,78,85,88) (73), peripheral arterial disease (PAD) (63), familial 
hypercholesterolaemia (FH) (70) and acute chronic obstructive pulmonary disease (COPD) (66) or 
specific ethnic groups (e.g. Asian hypercholesterolaemic populations) (75) (69) (36). Recommended 
interventions include foods e.g. milk (87), Dietary fish (72) or Black and green tea (94)), dietary 
patterns (e.g. whole grain diets (82), low GI diets (76) ) or supplements (e.g. selenium supplements 
(92), CoQ10 (89,96) and calcium supplementation (76) (94)), nutritional education and counselling 
programmes e.g. low sodium dietary advice and reduced sodium advice (73) and policy e.g. effects 
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of legislation ( to alter fat contents of foods, improved labelling, pricing initiatives and improved 
availability of healthier (12). Outcomes recommended included cardiovascular morbidity 
(12,65,72,73,75,82,85,88,91) and mortality (73,85,88,91,91), blood pressure (72,77,81,91,95), 
hormonal and lipid outcomes (91) (72,92), health related quality of life (HRQoL) (35,66,74,96) (64), 
and adverse events (74,85,88,95,96). These studies should be conducted in low and middle-income 
countries (69), primary care and the workplace compared with hospital settings (68), population and 
community level (35), United Kingdom healthcare and other settings (35), lower and higher income 
countries (72), low and middle-income countries (69), developing countries (69), population level 
(e.g. workplace, institutional, regulatory) (91) and international setting(36) 
Research gaps for chronic respiratory diseases:  
Future studies should include children (from birth) (57,59,60), adolescents (57) and adults with 
different types of asthma (e.g. chronic (52), exercise induced and well-controlled asthma (54,56), 
patients with different levels of asthma severity (58) and habitual consumers and non-consumers of 
coffee (58). Recommended interventions included specific foods containing caffeine (58) or omega-3 
Poly-unsaturated fatty acids (omega-3 PUFAs) (54) or dietary patterns (e.g. reduced calorie intake( 
52), dietary sodium manipulation (54)). Outcomes recommended included clinical outcome 
measures (e.g. lung function, asthma symptom scores, bronchoconstriction(56,58)), exercise 
tolerance (56), quality of life (30,52,56–59), adverse effects (56,57,59), the impact on work and 
school (56) and hospital utilisation (30,57). These studies should be conducted in low-income 
countries such as Africa (57). 
Research Gaps for Diabetes 
Future studies should include people who are overweight or pre-diabetic (defined as an impaired 
fasting glucose or moderately elevated HbA1c), young children with diabetes (106,108), adults with 
type 1 and 2 diabetes (110) (102,111) (97,107,109), with and without complications (e.g. diabetic 
kidney disease, diabetic neuropathy) (11) (112) or individuals with normal blood pressure (11). 
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Recommended interventions include food groups or foods such as whole grains (105), sweet potato 
(111) or those containing omega-3 PUFA (99), and cinnamon) (108), dietary patterns (e.g. low 
glycaemic index diets (106), sustained salt reduction (11)), supplements (e.g. vitamin B) (112) or 
nutritional education and counselling programmes e.g. impact of individual diabetes patient 
education (103). Outcomes recommended included the incidence of type 2 diabetes mellitus (104), 
all-cause mortality (102,104), glomerular filtration rate (97), cardiovascular diseases outcomes (left 
ventricular function and pulse wave) and blood lipid profiles (97), weight loss, quality of life (97,100–
102,104,106), validated measures of cognitive function (100), mood, depression and other aspects 
of functional status (110).  
Research gaps for obesity and overweight 
Future studies should include obese and overweight individuals (children from birth to 12 years) 
(37), adolescents and adults, parents in paediatric obesity interventions(121) and healthcare 
professionals (33). Recommended interventions include, dietary patterns (e.g. diet and physical 
activity, dietary and other behavioural interventions) (117) (119), nutrition education and 
counselling programmes (e.g. educational interventions other than brief face-to-face meetings such 
as weight management using e-health systems) (33) (113) (115)or whole foods (e.g chitosan) (34). 
Outcomes to be assessed include morbidity (34,118), mortality (34), obesity-related comorbidities 
(e.g. type 2 diabetes and cardiovascular disease) (120), quality of life (34,113,116,120,121) (115) or 
adverse effects(113,116,119,121). Trials should be reported according to standard reporting 
guidelines(127) (33,116). 
Research gaps for healthy diets 
Future studies should include people from culturally diverse backgrounds (123) and children aged 
five years and under (123). Recommended interventions included behavioural interventions 
delivered by health professionals (123), telephone or computer-based programmes, or mobile 
phones (123), and interventions delivered through preschools, play-groups, sports clubs, or co-
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operatives (123). Outcomes included adverse effects (e.g. increased family grocery costs, adverse 
effects on parent self-esteem or sense of competence) (123), use of tools validated to measure 
outcomes (such as sun protection habits, alcohol use, smoking status, frequency of healthy eating) 
(122) and perspectives from health professionals and clients about the interventions (124). These 
studies should be conducted in low-income (123), minority or indigenous communities (123), health 
services (123) and sports settings (122). 
 
Characteristics of primary studies included in Cochrane nutrition reviews addressing 
alternative nutrition supplements  
From the eligible NCD Cochrane nutrition reviews (n=98), we identified seven eligible reviews 
addressing alternative nutrition supplements (32,34,83,85,89,96,108). These reviews had a 
combined total of 59 included primary studies (no duplicates). We excluded eight non-English 
studies. The list of non-English primary studies which were excluded is presented in Additional Files 
(Table a8). A total of 51 primary studies were included in the analysis of reporting of COI, sponsors 
and author financial ties and their influence on study outcomes and authors conclusions. 
Table 3 below provides a brief summary of the characteristics of included primary studies. Studies 
addressing cancer, diabetes, and overweight and obesity all assessed a single alternative nutrition 
supplement, namely dietary flavonoids (128–135), cinnamon (136–145) and chitosan (146–159), 
respectively. Three alternative nutrition supplements (Coenzyme Q10 (160–172), creatine and 
creatine analogues (173–177) and garlic (178)) were assessed by studies addressing cardiovascular 
diseases. Forty-one primary studies were parallel randomised controlled trials and most primary 
studies addressing cancer were cohort studies (n=5) (128,131–133,135) and case-control studies 
(n=2) (129,134). A total of five of the 51 primary studies were conducted in four LMICs (Iran (166), 
Pakistan (141,142), India (162) and Thailand (144)) and none were conducted in Africa. The detailed 
characteristics of each individual included primary study is presented in Additional Files (Table a7) 
including: NCDs or nutrition-related risk factors and the population, interventions, comparison and 
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outcomes addressed, study design of primary study, the reporting of COI, funding sources and 
author-sponsor financial ties, the authors conclusion (favourable or unfavourable to sponsor and 
author-financial sponsor ties) and the country where the primary study was conducted.. 
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Table 3: Summary of characteristics of included primary studies  
NCD Grouping  Alternative Nutrition 
Supplement assessed 
(n studies) 
Population addressed  Study Design Country of study 
Cancer Dietary Flavonoids 
(n=8) (128–135) 




Case control (n=2) 
(128,134) 
Parallel RCTs (n=1) (130) 
USA (n=4) 











Patients with chronic heart failure (with reduced ejection 
fraction (HFREF) or normal ejection fraction (HFNEF), 
participants with chronic heart failure of any severity, Chronic 
heart failure with leA-sided and right-sided heart failure.  




Cross over RCTs (n=2) 
(169,179) 
 
Non RCTs (n=1) (162) 
USA (n=1) 
Italy (n=4)                          
Iran (n=1) 
India (n=1)   
Israel (n=1) 
Japan (n=2) 
Russia (n=1)               
Finland (n=1)    
Sweden (n=1) 
Germany (n=2)         
Denmark (n=1)         
Australia (n=1)  
New Zealand 
(n=1)  
South Korea (n=1)                                      





Adults >18 years of age with cardiovascular disease (essential 
hypertension, heart failure or myocardial infarction) 
Garlic (n=1) (178) Adults ≥ 18 years of age, with primary hypertension (systolic 
blood pressure > 140 mmHg and/or a diastolic blood pressure 
of > 90mmHg)  
 
Diabetes Cinnamon (n=10) 
(136–145) 
People with either type 1 or type 2 diabetes mellitus 
diagnosed using the standard criteria valid at the time of the 
beginning of the trial. 
Parallel RCTs (n=10) 
(136–145) 
UK (n=1) 
USA (n=4)                        
Pakistan (n=2) 
Thailand (n=1) 
Germany (n=1)                                
Netherlands (n=1)          







Adults >18 years and older defined as overweight or obese at 
baseline using body mass index (BMI) cut points and 
percentage excess weight compared with ideal weight/height 
tables.  
Parallel RCTs (n=14) 
(146–159) 
Finland (n=1)                  
UK (n=2) 
Canada (n=1)                  
USA (n=2)                                 
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Reporting of conflicts of interest, funding sources and author-sponsor financial ties  
Table 4 summarises the reporting of COI, funding sources and of the author-sponsor financial ties in 
full-text English primary studies primary studies (n=51) included in Cochrane nutrition reviews 
addressing alternative nutrition supplements and the four major NCDs ( cancer, cardiovascular 
diseases, chronic respiratory diseases and diabetes) and their nutrition-related risk factor (obesity 
and overweight). The author-sponsor financial ties are classified according to whether the sponsors 
are industry or non-industry related.  
Of the 51 full-text English primary studies included in Cochrane nutrition reviews addressing 
alternative nutrition supplements, 10/51 (19.6%) reported their conflicts of interest (128–
130,132,135,137,140,146,160,171). Of these, eight reported no COI (128–130,132,135,137,140,171) 
and two reported having existing conflict of interest. Of the two studies with existing COI, one 
author reported being the president of the company NxCare Inc., which manufactured and provided 
the alternative supplement chitosan (Calorie-care) (146) and the authors of the other study reported 
having conflict of interest with the company (Kaneka Co.) (160). 
Funding sources were disclosed in 27/51 (52.9%) studies (Table 4), of which 11 reported industry 
sponsors and 16 reported non-industry sponsors. Of those studies reporting industry sponsors, 
seven reported pharmaceutical industry sponsor s(e.g. Marshtech Ltd, London; Vanson inc.) 
(143,146,155,157,160,164,180), and four reported mixed funding sources including the 
pharmaceutical industry (e.g. Trippler Army Medical Center, Integrity Nutreceuticals International 
and US Department of Agriculture) (136,137,158,170). Of those studies reporting non-industry 
sponsors, eight reported government sponsors (e.g. National Center for Research Resources, 
National Center for Research Resources and National Institutes of Health) (128–
130,132,134,139,140,165), five reported mixed funding sources excluding food and pharmaceutical 
industry (e.g. Swedish Medical Research Council (4494 and 9515), the Swedish Heart and Lung 
Foundation and the Salus 60-year Medical Foundation) (131,133,135,138,174), and three reported 
non-profit sponsors (e.g. University Grants Commission/NWFP Agricultural University, Peshawar, 
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Pakistan) (142,167,172). None of the studies received funding from the food industry alone, mixed 
funding sources including the food Industry, mixed funding sources including the pharmaceutical and 
food industries, or from other for-profit entities.  
Author-sponsor financial ties were disclosed in 9/51 (17.6%) studies. Of these, one study reported that 
one author was an industry employee (146) and the remaining studies reported that authors received 
non-industry grants, fellowships or awards (128,129,132,134–136,155,158). Author-sponsor financial 
ties were reported separately from the conflicts of interest. 
Table 4: Reporting of conflicts of interest, funding sources and author-sponsor financial ties in 
primary studies (n=51)  
Domain n/N (%) 
COI disclosed 10/51 (19.6) 
Existing COI 2/10 (20) 
None 8/10 (80) 
  
Funding sources disclosed 27/51 (52.9) 
Industry Sponsors 11/27 (40.7) 
 Pharmaceutical  7/27 (25.9) 
 Mixed funding sources with pharmaceutical industry  4/27 (14.8) 
Non-industry Sponsors 16/27 (59.2) 
 Government 8/27 (29.6) 
 Mixed funding sources without pharmaceutical and food industry 5/27 (18.5) 
 Non-Profit 3/27 (11.1) 
  
Author-sponsor financial ties disclosed 9/51 (17.6) 
Industry author-sponsor financial ties  
 Current  or former employee of Pharmaceutical industry 1/9 (11.1) 
Non-industry author-sponsor financial ties  
 Non-industry grants 8/9 (88.8) 
 




Of the 11 studies which received industry funding, seven studies had favourable author conclusions 
(137,143,146,157,160,164,180) and four had unfavourable author conclusions (136,155,158,170). Of 
the 16 studies which received non-industry funding, eight had favourable 
(128,130,131,134,140,141,167,174) and eight had unfavourable author conclusions 
(128,132,133,135,138,139,165,172). One study with industry author-financial sponsor ties had 
favourable author conclusions (146) and of the eight studies with non-industry author-financial 
sponsor ties , one had favourable author conclusion (129) and seven had unfavourable author 
conclusions (128,132,134–136,155,158).  
 
Influence of funding source on author’s conclusions in included primary studies 
Table 5 shows the association between author conclusions with funding sources and author-sponsor 
financial ties in included primary studies that reported funding sources (n=36). Of the 27 studies that 
reported funding sources, and nine studies that reported author-sponsor financial ties, 12 studies 
reported having industry-related funding sources and author-sponsor financial ties and 24 studies had 
non-industry funding sources and author-sponsor financial ties (Table 5). Of the 12 studies which 
reported having industry sponsors and author-sponsor financial ties, eight had favourable and four 
had unfavourable author conclusions. Of the 24 studies with non-industry funding sources and author-
financial sponsor ties, eight studies had favourable and eight had unfavourable author conclusions.  
We found no evidence of an association between authors making favourable conclusions and having 
industry sponsors and author-financial sponsors (8/12) compared with having non-industry sponsors 
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Table 5: Associations between author conclusions with sponsor and author-sponsor financial ties in 
primary studies  
Primary study 
results 
Funding sources and  author-financial sponsor ties 
Author 
conclusions 
Total Industry Non-industry Fisher Exact test 
p value 
 36 12 14  
p= 0.289 Favourable  18 8 10 
Unfavourable  18 4 14 
 
  





Reporting of “implications for research” section according to EPICOT+ framework 
In 98 Cochrane nutrition reviews addressing the four major NCDs (cancer, cardiovascular diseases, 
chronic respiratory diseases and diabetes), nutrition-related risk factor (obesity) and healthy diets, 
we found that the most reported EPICOT+ items were the intervention, study design, outcomes, 
population and the timeframe and the lesser reported items were the comparison, the evidence and 
the burden of disease. These findings are consistent with findings in a similar previous bibliometric 
analysis of Cochrane HIV reviews, where the most reported EPICOT+ framework elements in the 
“implications for research” section were the population, intervention, outcome and time frame, and 
the lesser reported elements were the evidence, comparison and burden of diseases (181). 
According to Brown et.al, unlike the evidence, population, intervention, comparison and outcome, 
reporting the burden of disease in the “implications for research” section is optional (20). This 
maybe the cause of the lesser reporting of the burden of disease seen in our study. Considering the 
burden of disease when formulating research recommendations is important as this will inform 
researchers and policy makers of the settings for which urgent research is needed. Mbuagbaw et.al 
hypothesized that the lack of reporting of the evidence item may be explained by the fact that 
authors allude to the evidence in the in the meta analyses and they might find it repetitive to do the 
same in the “implications for research” section (181). In addition, some of the included reviews in 
our analysis presented the results of their meta-analyses as ‘Summary of Findings tables’, where the 
certainty of evidence for the main outcomes of each review is evaluated by review authors using the 
GRADE certainty framework. This has become a prerequisite for conducting Cochrane systematic 
reviews according to the Cochrane Handbook (16). 
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Summarising research gaps in primary research based on the “implications for 
research” section of Cochrane nutrition reviews 
Implications for research 
From analysing the “implications for research” section of 98 Cochrane nutrition reviews addressing 
the four major NCDs and their nutrition-related risk factors, our findings suggest the need for more 
RCTs, more studies with different populations, interventions, outcomes and larger studies in all NCD 
groupings. Our results are comparable with findings in a similar study in Cochrane reviews 
addressing HIV which suggested the need for more RCTs overall, more studies with different 
outcomes and more studies with different interventions (181). Recommendations for future studies 
with a design other than randomised control trials (cohort studies, qualitative studies and Systematic 
reviews) were highlighted in very few studies for cancer, chronic respiratory diseases and obesity 
and overweight. More future studies with longer duration of follow up were highlighted for all NCD 
groupings, however studies of longer duration may be done as much as resources allow. 
Research Gaps 
We identified specific research gap areas (population, intentions, comparison, outcomes and study 
design) in the evidence base of nutrition and the four major NCDs and their nutrition-related risk 
factors for which future research should address. The research gaps identified in Cochrane nutrition 
reviews across all NCDs and nutrition-related risk factors pointed to issues relating to quality of 
studies, settings in which studies are to be conducted and the execution and reporting of studies. 
The need was identified for future trials to minimise risk of bias by implementing proper methods of 
randomisation, allocation concealment and blinding, ITT or PP analyses and explicitly describing 
these methods when reporting trials. More research in LMICs was highlighted in reviews addressing 
cardiovascular diseases, chronic respiratory diseases and obesity and overweight, whilst more 
research in high income countries was highlighted in reviews on cardiovascular diseases. 
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Future researchers were recommended to adopt Standard Protocol Items: Recommendations for 
Interventional Trials (SPIRIT) guidelines (guidelines which provide guidance on how researchers 
should fully describe the contents of protocols for clinical trials) (126) when conducting RCTs for 
cancer. To achieve standardised reporting of interventional trials in cancer, cardiovascular diseases 
and obesity and overweight, researchers were recommended to adopt Consolidated Standards for 
Reporting of Trials (CONSORT) guidelines (guidelines which provide guidance on reporting how a trial 
was designed, analysed, and interpreted; and the progress of all participants through the trial) (127).  
 
Reporting of conflicts of interest, funding sources and author-sponsor financial ties 
In 51 primary studies included in Cochrane nutrition reviews addressing alternative nutrition 
supplements and the four major NCDs and their nutrition-related risk factors, we found that conflicts 
of interest were not well reported. Our findings of poor reporting of COI are similar to previous 
studies that explored the reporting of COI in case-control and cohort studies on effects of dairy 
consumption and whole grain food consumption on cardiovascular outcomes and mortality, as well 
as in RCTs of nutritional interventions addressing obesity (182–184).  
In our analysis, funding sources were reported in more than half of the included primary studies, and 
nearly a quarter of these were industry sponsors. The lower proportion of reported industry 
sponsors in our study was also found in studies exploring the influence of funding sources in primary 
studies addressing effects of nutrition interventions on obesity and effects of consumption of dairy 
products on cardiovascular outcomes and mortality (182,185). The lower proportion of reported 
industry sponsors might be due to the lack of disclosure of industry sponsors by primary study 
authors. The disclosure of author-sponsor financial ties was poor, with only 1 study reporting 
industry author-sponsor financial ties. These results are consistent with findings of a meta-analysis 
of Cochrane reviews of drug trials in which author-sponsor financial ties for included RCTs were 
poorly reported (186). 
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Influence of sponsors and author-sponsor financial ties on author conclusions in 
included primary studies 
Based on included primary studies which reported their funding sources and author-financial 
sponsor ties, we found no association between authors making favourable conclusions and having 
industry sponsors compared with having non-industry sponsors. Our results are consistent with 
findings from a meta analyses of case control and cohort studies examining the effect of dairy food 
intake on cardiovascular disease and mortality and another meta analyses of cohort studies and 
reviews exploring the association of industry sponsorship with outcomes of nutrition studies, in 
which they found no association between industry sponsors and author conclusions(182,187). . Our 
findings are inconsistent as well with a previous study which explored the reporting of sponsors, COI 
and author financial ties and their influence on study outcomes and author conclusions in systematic 
reviews of artificially sweetened beverages on weight outcomes (21).. The differences in findings 
may be due to that our sample size was smaller and the association between industry author-
sponsor financial ties and author conclusions may have not been dictated. 
From our study and other previous studies, it is apparent that COI, sources of funding and author-
sponsor financial ties is under reported. The under reporting of COI, sponsors and author-sponsor 
financial ties obscures a true picture of the COI where it exists. This limits the interpretation and 
judgement of the accuracy of research findings and the application of research findings by 
stakeholders (e.g. scientists, readers, policy makers, clinicians) since possible bias introduced by the 
sponsors and by the author relationship with sponsors is obscured. Searching online for disclosure of 
COI, sponsors and author-sponsor financial ties is a possibility, however it might be cumbersome and 
time consuming, and this is subject to whether the declarations were recorded or not online. To 
improve the reporting of COI, funding sources, and author-sponsor financial ties, journals are urged 
to include this information in abstracts of articles submitted to PubMed Central (online database for 
biomedical literature) (188). 




Our study has several limitations. The search for nutrition reviews addressing the four major NCDs 
and their nutrition-related risk factors was done up to 2015, and thus we may have missed relevant 
Cochrane reviews published thereafter. Although we used the most recent updates of the included 
reviews, our search remained limited, the research gaps we identified were restricted to those 
reported in Cochrane systematic reviews. 
The subset of primary studies we analysed was from a non-randomised sample of Cochrane reviews 
addressing alternative nutrition supplements, therefore our findings are only specific to these 
primary studies and Cochrane reviews. In our analysis, we included full-text English primary studies 
only and excluded primary studies published in languages other than English. Our findings may have 
been different if we had included the non-English primary studies. We did not contact the authors 
for undisclosed COI, funding sources and author financial ties or search for these declarations online, 
as a result we may have missed existing COI, funding sources and author financial ties. Our 
classification of sponsors was done based on a simple categorisation of the type of funder only, and 
we did not explore the actual origin of the funding for each funder. This may have led to some 
misclassification, for example, one study was classified as non-industry (not for profit charity 
organisation) yet, the organisation is financially supported by food industries. 
Conclusions 
Our findings show that EPICOT+ Framework items were not well reported in the “implications for 
research” section in most reviews. We identified research gaps in the field of nutrition and NCDs 
that may be useful to researchers, funders, and policy makers when planning future research. 
Author-sponsor financial ties may have influenced author conclusions, however, we cannot state this 
with certainty since the sample analysed was small. Future studies exploring the influence of 
sponsors and author-sponsor financial ties on study conclusions should have larger sample sizes. The 
poor disclosure of COI, funding source and author-sponsor financial ties in included primary studies 
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warrants the need for journals and their editorial boards to urge authors to report COI, sponsors and 
author-financial sponsor ties, especially for studies that received industry sponsorship. 
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EPICOT+ Framework: Evidence, Population, Intervention, Comparison, Outcome, Timeliness, Study 
design and Burden of disease Framework 
EuroQoL: Euro Quality of Life 
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HOMA-IR: homeostasis model assessment of insulin resistance 
HRQoL: Health related Quality of Life 
ITT: Intention to treat analysis 
LMICs: Low to middle income countries 
LeA: ventricular ejection fraction 
 LDL: Low density lipoprotein 
MI: Myocardial infaction 
MSG: Monosodium glutamate 
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Additional Files   
 
Table a1: Characteristics of Cochrane nutrition reviews addressing cancer  
Domain  Characteristics 
NCD Grouping or 






NCDs and nutrition 
related risk factors 
addressed in review 
Cancer, Gastrointestinal cancer, neuroblastoma, head and neck cancer, 
colorectal cancer, colorectal carcinoma, colorectal neoplasms, cancer 
cachexia, prostate cancer and adenomatous polyps 
 
Population Healthy people :adults ≥ 18 years 
 
People at high risk e.g. high risk of gastrointestinal cancer, People with 
high-risk neuroblastoma, Healthy adults at higher risk of colon cancer 
due to family history, previous adenomatous polyps, or inflammatory 
bowel disease. 
 
People with disease: e.g.  people with non-gastrointestinal cancer, 
cancer patients (adults and children ages > 1 year) who received 
chemotherapy causing neutropenia, adult patients with head and neck 
cancer receiving radiotherapy and/or chemotherapy, Children and 
young people (ages≤ 21 years) with malignant disease, patients with 
incurable or advanced cancer and cachexia 
 
People with comorbidities e.g. Adult participants (aged 18 years or 
over) with vitamin D deficiency or a disease but are in stable condition 
 
Intervention Foods e.g. green tea,  
 
Diets and dietary patterns e.g. low bacterial diets,  
 
Feeding modalities e.g. enteral feeding for head and neck cancer 
 
Nutritional products and nutrients and bioactive non-nutrients e.g. 
antioxidants (selenium, Vitamin C, Vitamin D), dietary fiber  
 





2007 to 2020 
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Table a2: Characteristics of Cochrane nutrition reviews addressing cardiovascular diseases 
Domain Characteristics 
NCD Grouping of 






NCDs and nutrition 
related risk factors 
addressed 
Cardiovascular diseases, myocardial infaction, heart failure, coronary 
heart disease, stroke, blood pressure/hypertension, peripheral arterial 
occlusive disease (PAOD), arterial or venous leg ulcers, intermittent 
claudation, peripheral arterial disease of the lower limb, 
cholesteroleamia 
 
Population Healthy people :adults ≥ 18 years without cardiovascular disease, 
normotensive people of different ages 
 
People at high risk e.g. Adults ages≥18 with essential hypertension at 
any risk, Persons with normal or elevated blood pressure, Adults of all 
ages at high risk of cardiovascular diseases, Participants with history of 
stroke 
 
People with disease: e.g. Adults ages≥18 years with existing 
cardiovascular disease (myocardial infarction, chronic heart failure,  
peripheral arterial occlusive disease, intermittent claudication, lower 
limb peripheral arterial disease (PAD)) 
 
People with comorbidities e.g. Adults ages≥18 with essential 
hypertension at any risk, diagnosed as overweight or obese, children 
and adults with familial hypercholesterolaemia, acquired (not familial) 
hypercholesterolaemia 
 
Intervention Foods e.g. cocoa powder, garlic, green or black tea, 
Nutritional products and nutrients and bioactive non-nutrients: oral 
zinc sulphate, potassium, calcium, selenium, Coenzyme Q10. 
  
Diets and dietary patterns e.g. Mediterranean-style diet, lipid  lowering 
diet, increased vegetable consumption 
                                                                                                                                           
Nutrition education and counselling programmes e.g. dietary advice to 
reduce blood cholesterol, dietary interventions involve verbal or 
written advice 
 




Stellenbosch University  https://scholar.sun.ac.za
74 
 
Table a3: Characteristics of Cochrane reviews addressing chronic respiratory diseases 
Domain  Characteristics 
NCD Grouping of 
nutrition related risk 
factors 




NCDs and nutrition 
related risk factors 
addressed 
Asthma 
Population People at high risk e.g. Children at high risk of developing atopy or 
asthma  
 
People with disease: e.g. Adults and children with allergic asthma (e.g. 
sensitivity to aspirin or tartrazine), exercise induced asthma and 
bronchoristiction and overweight or obese adults and children with 
asthma 
 
Intervention Foods e.g. Caffeine or coffee,  
Nutritional products and nutrients and bioactive non-nutrients: 
selenium, tartrazine, Vitamin C, Vitamin E, 
 
Diets and dietary patterns e.g. dietary calorie reduction, marine n-3 
fatty acids to the diet and/or any manipulation of dietary intake of 
marine n-3 fatty acids, allergen reducing interventions (inhalant 
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Table a4: Characteristics of Cochrane nutrition reviews addressing diabetes 
Domain  Characteristics 
NCD Grouping of 






NCDs and nutrition 
related risk factors 
addressed 
Cognitive impairment and dementia, Type 1 and 2 Diabetes, Diabetes 
Kidney disease, Diabetic neuropathy 
 
Population People at high risk e.g. Healthy individuals with/ at  least one major risk 
factor for type 2 diabetes, prediabetic individuals, Individuals with 
insulin resistance 
 
People with disease: e.g. Adults with diabetic retinopathy, diabetic 
retinopathy, diabetes kidney disease, individuals with type 1 or type 2 
diabetes. 
 
Intervention Foods e.g whole grain foods, , 
Nutritional products and nutrients and bioactive non-nutrients: 
vitamin C/superoxidase dismutase, Vitamin B, cinnamon,zinc 
 
Diets and dietary patterns e.g Diet with or without physical activity, , 
low glycaemic index (GI) or low glycaemic load diet 
 
Nutrition education and counselling programmes e.g individual patient 
education for managing type 2 diabetes, dietary advice for reducing 
weight and severity of type 2 diabetes, Computer-based software 
applications for self-management of type 2 diabetes 
 
Policy programmes or system programmes e.g treatment approved by 
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Domain  Characteristics 
NCD Grouping or  
nutrition related risk 
factors 





Diseases or nutrition 
related risk factors  
 
Overweight and obesity 
Population People with disease: e.g overweight or obese  individuals (children and 
adolescents ages 0 to 18 years and adults ages≥ 18 years) , fully-
qualified health professionals, working with adults and children with 
overweight or obesity, in healthcare settings 
 
Intervention Foods e.g green tea 
Nutritional products and nutrients and bioactive non-nutrients: 
Chromium picolinate (CrP),chitosan, 
 
Diets and dietary patterns e.g. dietary, physical activity and/or 
behavioural therapy for weight loss, Physical, psychological and Dietary 
and nutritional interventions, low glycaemic index or low glycaemic 
load diet 
 
Nutrition education and counselling programmes e.g. intervention 
directed at the healthcare professional or organisation of care to help 
implement weight reduction interventions in children and adults with 
overweight or obesity. Transtheoretical model (TTM) stages of change 
(SOC) combined with dietary and /or physical activity intervention. 
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Table a6: Characteristics of Cochrane nutrition reviews addressing healthy diets  
Domain  Characteristics 
NCD Grouping or  







Diseases or nutrition 
related risk factors  
Chronic Diseases, healthy diets, healthy behavior change 
 
Population Healthy individuals e.g. children ages≤ five years ,Individuals ages ≤18 
years,People of all ages 
 
Intervention Nutrition education and counselling programmes e.g. educational, 
experiential, health promotion and/or psychological or family or 
behavioural therapy or counselling or management or structural or 
policy or legislative reform interventions, designed to increase 
consumption of fruit or vegetables or both, chronic disease prevention 
and management for adherence to dietary advice. 
 
Policy programmes or system programmes e.g policy intervention 
implemented through sporting organisations to instigate and/ or 
sustain healthy behaviour change, intention to change behaviour, or 
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Table a7: Characteristics of included primary studies included in Cochrane nutrition reviews 
addressing the four major NCDs and their nutrition related risk factors 
Table a7 is a table of characteristics of the full-text English primary studies (n=51) included in 
Cochrane nutrition reviews addressing alternative nutrition supplements and the four major NCDs 
and their nutrition related risk factors.  
Cochrane review title (Accession number)            Chitosan for overweight or obesity (CD003892) (34) 
Colombo 1996 
Study Title Nutritional aspects of chitosan employment in hypocaloric diet (148) 
Non communicable disease  NA 
Nutrition-related risk factor Overweight and obesity 
Population Ambulatory males and females aged 20-70 years with mild obesity 
(overweight by 10% to 25% as compared with ideal weight-height 
tables) and hyper lipoproteinemia.  
Intervention 2 capsules twice daily (dose not stated) of “Somagril” (Lifepharma) 
(chitosan, guar’s meal, ascorbic acid and other micronutrients) with 
meals (lunch/dinner). Co-interventions :Low calorie diet (1000 kcal 
based on 34% fat, 41% carbohydrate and 25% protein) 
Comparison 2 capsules twice daily (dose and composition not stated).capsules 
advised to be taken with main meals (lunch/dinner). Co-interventions: 
low calorie diet (1000 kcal based on 34% fat, 41% carbohydrate and 
25% protein) 
Outcome Outcomes assessed following 4 weeks of treatment:                                                     
Body weight, percentage overweight, serum lipids, side effects, quality 
of life, diet and drug compliance, appearance of faeces, haematological 
and blood chemistry analysis  
Study Design Parallel randomised Control Trial 
Country  Italy 
Conflict of interest 
disclosed 
No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 




ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Girola 1996 
Study Title Dose effect in lipid-lowering activity of a new dietary integrator 
(chitosan, Garcinia cambogia extract and chrome)(149) 
Non-communicable disease NA 
Nutrition-related risk factor Overweight and obesity 
Population Ambulatory males and females aged 20-70 years with mild obesity 
(overweight by 10% to 25% as compared with ideal weight-height 
tables) and hyper lipoproteinemia.  
Intervention Group 1: 2 capsules daily of “Colenon” (480 mg chitosan, garcinia 
cambogia extract and chrome) during main meals (lunch/dinner). 
Group 2: 1 capsule daily of “Colenon”  (240mg chitosan, garcinia 
cambogia extract and chrome) during main meals (lunch/dinner). 
Co-interventions: low calorie diet (1000 kcal based on 34% fat, 41% 
carbohydrate and 25% protein) 
Comparison 2 capsules daily (composition not stated) during with main meals 
(lunch/dinner). 
Co-interventions: low calorie diet (1000 kcal based on 34% fat, 41% 
carbohydrate and 25% protein) 
Outcome Outcomes assessed following 4 weeks of treatment:                                                                 
Body weight, percentage overweight, serum lipids, side effects, quality 
of life, diet and drug compliance, appearance of faeces, haematological 
and blood chemistry analysis. 
Study Design Parallel randomised Control Trial 
Country  Italy 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 




ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Giustina 1995 
Study Title Weight-reducing regimes in obese subjects: effects of anew dietary 
fiber integrator (150) 
Non-communicable disease NA 
Nutrition-related risk factor Overweight and obesity 
Population Ambulatory males and females aged 20-70 years with mild obesity 
(overweight by 10% to 25% as compared with ideal weight-height 
tables) and mild hypertension.  
Intervention 2 tablets twice daily of “Nofat” ( chitosan, guar’s meals, ascorbic acid 
and other micronutrients) during main meals (lunch/dinner).                                              
Co-interventions: low calorie diet(1000-100kcal based on 34% fat, 41% 
carbohydrate and 25% protein) 
Comparison 2 tablets twice daily (composition not stated) during main meals 
(lunch/dinner). Co-interventions: low calorie diet(1000-100kcal based 
on 34% fat, 41% carbohydrate and 25% protein) 
Outcome Body weight, percentage overweight, arterial pressure (systolic and 
diastolic), heart, respiratory rate, side effects, quality of life, diet and 
drug compliance and appearance of faeces were assessed at 7,14, 21, 
and 28 days of treatment. Hematological and blood chemistry analysis 
at 28 days post treatment 
Study Design Parallel randomised Control Trial 
Country  Italy 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
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Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Ho 2001 
Study Title In the absence of dietary surveillance, chitosan does not reduce plasma 
lipids or obesity in hypercholesterolaemic obese asian subject (156) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Normoglycaemic obese males and females (body fat % > 20% in males 
and > 30% in females) who were hypercholesterolaemic (total 
cholesterol>5.20 mmol/L) and had no history of chronic illnesses. 
Intervention Run-in phase comprising the first 4 weeks followed by  
4 capsules of 257 mg “Absorbitol” (257 mg ShellfishL112 Absorbitol, 
175 mg corn starch, 10 mg calcium carbonate, 5 mg magnesium 
stearate) 3 times daily for 12 weeks. Co-interventions: no dietary 
restriction 
Comparison Run-in phase comprising the first 4 weeks followed by 
4 capsules of placebo (450 mg cornstarch) 3 times daily for 12 weeks, 
Co-interventions: no dietary restriction 
Outcome Outcomes assessed at enrolment, baseline (following 4 weeks placebo 
run-in phase) and after 12 weeks of treatment: Body weight, BMI, waist 
and hip circumferences, blood pressure (systolic and diastolic), fat free 
mass, % body fat, serum lipids, and fasting insulin, adverse events. 
Study Design Parallel randomised Control Trial 
Country  Singapore 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 





Study Title Evaluating efficacy of a chitosan product using a double-blinded, 
placebo controlled protocol (157) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Overweight Adults.  
Intervention 6 tablets of 500 mg chitosan, and 1mg per tablet of beta-glucan, snow 
white oat fibre, betamine HCL and aloe saponins daily .Co-
interventions: Self-monitored behavioural modification programme 
consisting of a work book for estimating caloric intake, calculator with 
nutritional information on 5000 foods, log book for calculating and 
estimating daily calorie balances and dietary fat intake, pedometer and 
recording of daily steps 
Comparison Placebo group: 6 tablets  of Polylactic acid daily.Co-interventions: Self-
monitored behavioral modification programme consisting of a work 
book for estimating caloric intake, calculator with nutritional 
information on 5000 foods, log book for calculating and estimating daily 
calorie balances and dietary fat intake, pedometer and recording of 
daily steps 
Control group: Minimum intervention group which followed a 
programme of their own choosing 
Outcome Outcomes assessed at baseline and after 60 days of treatment: Body 
weight (lbs), fat mass, fat free mass, % body fat, serum lipids 
Study Design Parallel randomised Control Trial 
Country  United States of America 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Health and Medical Research Center , San Antonio Texas 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 





Study Title A new approach to the treatment of obesity: chitosan’s effects on body 
weight reduction and plasma cholesterol’s levels(147) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and Overweight 
Population Obese males and females aged 30 and 80 years old, with 25% excess 
body weight. 
Intervention 4 tablets 250 mg of  chitosan (purified electrostatically charged 
chitosan (PAT RM q5A 000 772).) daily ,just before main meals.  
Co-interventions: low calorie diet (1200 kcal based on 30% fat, 45% 
carbohydrate and 25% protein) 
Comparison Comparator 1: 4 placebo tablets daily (composition not stated) just 
before main meals  
Co-interventions: low calorie diet (1200 kcal based on 30% fat, 45% 
carbohydrate and 25% protein);  
Comparator 2: 4 placebo tablets daily (composition not stated).                                   
Capsules advised to be taken just before main meals. 
Co-interventions: none (usual diet) 
Outcome Body weight, BMI, % body fat, emochrome, iron, electrolytes, 
transaminase, lipids, glucose, urea nitrogen and creatinine, side effects, 
well-being and appetite. 
Study Design Parallel randomised control trial 
Country  Italy 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Ni Mhurchu 2004 
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Study Title The effect of the dietary supplement, chitosan, on body weight: a 
randomised controlled trial in 250 overweight and obese adults(158) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Overweight or obese (BMI 28-50kg/m2) males and females ages≥ 18 
years who wished to lose weight. 
Intervention 4 capsules of 250 mg chitosan (beta-chitosan derived from NZ squid 
pens, molecular weight of 130,000, and deacetylation was 75.5%.) 
three times daily for 24 weeks, 30 minutes before meals.  
Co-interventions: standardised dietary and lifestyle advice 
Comparison 4 capsules of 250 mg maize cornflour three times daily for 24 weeks.  
Co-interventions: standardised dietary and lifestyle advice 
Outcome Outcomes assessed at 4-weekly visits and overall response was 
measured over entire 24-week period: Body weight, BMI, waist 
circumference, % fat, blood pressure (systolic and diastolic), glucose, 
serum lipids,  vitamin A, beta-carotene, vitamin D, prothrombin time, 
health-related quality of life, adverse events, adherence to treatment, 
faecal fat (subgroup of 50 volunteers) .  
Study Design Parallel randomised Control Trial 
Country  New Zealand 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Health research Council of New Zealand and Healtheries of New 
Zealand Ltd 
Author-financial sponsor 
ties  disclosed 
Yes 
Name of Author-financial 
sponsor ties   
CNM and AR held fellowships from the National Heart Foundation of 
New Zealand 
Author’s conclusions Unfavourable to financial sponsor and author-financial sponsor ties 
  
Pittler 1999 
Study Title Randomized, double-blind trial of chitosan for body weight 
reduction(155) 
Non-communicable disease NA 
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Nutrition-related risk factor Obesity and overweight 
Population Participants 18 to 60 years of age, BMI ranging from 23.9±28.5kg/m2 
for women and 25.0±29.9kg/m2 for men. 
Intervention 4 capsules of 250mg chitosan (deacetylated chitin biopolymer) daily for 
28 consecutive days. Co-interventions: normal diet 
Comparison 4 capsules of indistinguishable placebo twice daily for 28 consecutive 
days. Co-interventions: normal diet. 
Outcome Medical history taken at baseline. Dietary intake recorded in food diary, 
routine glucose measurement, body weight, height, blood pressure and 
quality of life using the SF-36, Blood concentration of total cholesterol, 
triglycerides, vitamin A, D (as 25-hydroxy vitamins D2 and D3), E, and K, 
and b-carotene, frequency of adverse effects (AEs) all at baseline, after 
14 and 28 days of treatment. Compliance was monitored by counting 
the remaining capsules after the final study visit. 
Study Design Parallel randomised Control Trial 
Country  United Kingdom 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Marshtech Ltd, London 
Author-financial sponsor 
ties  disclosed 
Yes 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Unfavourable to financial sponsor and author-financial sponsor ties 
  
Schiller 2001 
Study Title A randomized, double-blind, placebo-controlled study examining the 
effects of a rapidly soluble chitosan dietary supplement on weight loss 
and body composition in overweight and mildly obese individuals(180) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Overweight and mildly obese (BMI 27-40) but otherwise healthy 
females aged 21-55 years, with a stable weight history of at least 6 
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months and a history of daily fat consumption greater than or equal to 
30% of calories.  
Intervention 3 capsules of 500 mg LipoSan Ultra (>90% chitosan  and  <10%  
succinicacid, deacetylation value of  >78%,  viscosity of approx. 155 
mPas, molecular weight >100,000 daltons) twice daily for 8 weeks e 
taken immediately prior to 2 largest meals of the day. Co-interventions: 
normal diet or exercise routines 
Comparison 3 capsules of 500 mg maltodextrin-semolina flour blend twice daily for 
8 weeks. Co-interventions: normal diet or exercise routines 
Outcome Outcomes assessed at baseline and 8 weeks: Body weight, BMI, waist-
to-hip ratio, % body fat, % lean body mass, fasting serum lipid levels, 
fecal fat (in a subset of 7 participants). Beck depression inventory, 
medical outcome survey (short form 36), diet (food frequency 
questionnaire and diet diary), functional gastrointestinal and 
elimination symptoms. 
Study Design Parallel randomised Control Trial 
Country  United States of America 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Vanson Inc 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Sciutto 1995 
Study Title Lipid-lowering effect of chitosan dietary integrator and hypocaloric diet 
in obese subjects(152) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Ambulatory males and females aged 20-70 years with mild obesity 
(overweight by 10% to 25% as compared with ideal weight-height 
tables), mild hypertension, and hyper lipoproteinemia.  
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Intervention 2 tablets twice daily of “Somagril” (chitosan, guar’s meals, ascorbic acid 
and other micronutrients) for 4 weeks taken with main meals 
lunch/dinner). Co-interventions: low calorie diet (1000 kcal based on 
34% fat, 41% carbohydrate and 25% protein) 
Comparison 2 placebo tablets 500mg of the maltodextrin-semolina flour blend twice 
daily for 4 weeks.  
Co-interventions: low calorie diet (1000 kcal based on 34% fat, 41% 
carbohydrate and 25% protein) 
Outcome Body weight, percentage overweight, arterial pressure (systolic and 
diastolic), incidence of side effects, quality of life, diet and drug 
compliance, appearance of faeces were assessed at 7, 14, 21, and 28 
days of treatment. Serum cholesterol triglycerides, were assessed at 0, 
7, and 28 days. Hematological and blood chemistry analysis (were 
assessed at 0 and 28 days 
Study Design Parallel randomised Control Trial 
Country  Italy 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Veneroni 1996 
Study Title Effect of a new chitosan dietary integrator and hypocaloric diet on 
hyperlipidemia and overweight in obese patients(153) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Ambulatory males and females aged 20-70 years with mild obesity 
(overweight by 10% to 25% as compared with ideal weight-height 
tables), and hyperlipidemia.  
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Intervention 2 tablets of “Nofat” (chitosan, guar’s meals, ascorbic acid and other 
micronutrients) for 4 weeks twice daily taken with main meals 
(lunch/dinner).Co-interventions: low calorie diet (1000 kcal based on 
34% fat, 41% carbohydrate and 25% protein) 
Comparison 2 tablets twice daily for 4 weeks with main meals (lunch/dinner. Co-
interventions: low calorie diet (1000 kcal based on 34% fat, 41% 
carbohydrate and 25% protein) 
Outcome Body weight, percentage overweight, diet, physical fitness program and 
drug compliance, appearance of faeces, incidence of adverse events, 
quality of life were assessed at 0, 7, 14, 21, and 28 days of treatment. 
Serum cholesterol, triglycerides, hematological and blood chemistry 
analysis were assessed at 0 and 28 days of treatment. 
Study Design Parallel randomised Control Trial 
Country  Italy 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Williams 1998 
Study Title A double-blind, placebo-controlled evaluation of the effects of RW94 
on the body weight of both overweight and obese healthy 
volunteers(159) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Male and female adult volunteers aged 23-57 years, healthy but 
otherwise overweight meeting standard inclusion criteria for Phase I 
clinical trials.  
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Intervention  5g RW94 powder stirred into a glass of fruit squash 3 times daily for 6 
weeks taken 30 minutes after food. Co-interventions: normal diet, 
smoking or drinking habits  
Comparison 5g maize starch stirred into a glass of fruit squash 3 times daily for 6 
weeks taken 30 minutes after food. Co-interventions: normal diet, 
smoking or drinking habits  
Outcome Outcomes assessed at 0, 1, 2, 3, 4, 5, and 6 weeks: Body weight, state 
of health, adverse events.  
Study Design Parallel randomised Control Trial 
Country  United Kingdom 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Woodgate 2003 
Study Title Double-blind study evaluating the effects of a proprietary blend of 
glucomannan and chitosan on weight loss in overweight adults/ Effects 
of a stimulant-free dietary supplement on body weight and fat loss in 
obese adults: a six-week(146) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Obese (BMI >/= 30) male and female volunteers aged 20- 50 years.  
 
Intervention 2 capsules of chitosan (glucomannan, chitosan, fenugreek, G sylvestre, 
and vitamin C (1 capsule = 1395 mg) three times daily for 6 weeks 
taken before 1 hour meals.Co-interventions: participants instructed to 
continue their regular diet and exercise patterns 
Comparison 2 capsules of rice flour three times daily for 6 weeks taken before 1 
hour meals.Co-interventions: normal diet and exercise patterns 
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Outcome Measured at baseline and 6 weeks: Body weight, % body fat, fat mass, 
lean body mass, BMI, blood pressure, resting heart rate, upper 
abdominal circumference, waist and hip circumferences. 
Study Design Parallel randomised Control Trial 
Country  Canada 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
Name of Financial sponsor NxCare Inc. (Guelph, Ontario, Canada) 
Author-financial sponsor 
ties  disclosed 
Yes 
Name of Author-financial 
sponsor ties   
Derek E. Woodgate, MSc, stated that He is the president and owner of 
NxCare Inc.,which produces the dietary supplement containing 
glucomannan, chitosan, fenugreek, Gymnema sylvestre, and vitamin C 
(trade name Calorie-  
Author’s conclusions Favourable to financial sponsor and author-financial sponsor ties 
  
Wuolijoki 1999 
Study Title Decrease in Serum LDL Cholesterol with Microcrystalline Chitosan(154) 
Non-communicable disease NA 
Nutrition-related risk factor Obesity and overweight 
Population Healthy women ages 18 to 60 years, BMI of 28-34.99, using a reliable 
contraceptive (in women at fertile age). 
Intervention 3 capsules containing microcrystallined chitosan (400 mg + 50 mg 
auxiliary agents/capsule daily taken just before lunch and dinner for 8 
weeks.Co-interventions: normal living routines and diet 
Comparison 3 capsules of starch 2 times daily taken just before lunch and dinner for 
8 weeks. Co-interventions: normal living routines and diet. 
Outcome Serum Lipids Fe++, transferrin, total A and E vitamins, alanine-amino 
transferase (ALAT), aspartate-amino transferase (ASAT), alkaline 
phosphatase, creatinine, Na+, K+,  adverse events, body weight, and 
compliance  
Study Design Parallel Randomised control trial 
Country Finland 
COI disclosed No 
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Financial sponsor disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Cochrane Review title (Accession number): Creatine and creatine analogues in hypertension and 
cardiovascular disease (CD005184) (83)  
Ferraro 1996 
Study Title Hemodynamic effects of creatine phosphate in patients with congestive 
heart failure: a double-blind comparison trial versus placebo(173) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Hospitalised patients (12 men, 1 woman, mean age 52 ± 8 years) with 
Heart failure. NYHA class II-II 
Intervention Intravenous infusion of 6 gram creatine phosphate followed by 2 days' 
washout interval from CP, followed by a 4-day treatment period of 
placebo(50 mg mannitol) daily in two intravenous administrations, 
diluted in 50ml NaCl 0.9% 
Comparison Intravenous infusion of  placebo(50 mg mannitol), followed by 2 days' 
washout interval from placebo followed by a 4-day treatment period of 
receiving 6 gram creatine phosphate daily in two intravenous 
administrations, diluted in 50ml NaCl 0.9% 
Outcome Mono-bidimensional echo at baseline,15 rnh after treatment infusion, 
and 12 h after the end of short-term CP or placebo infusion on the basis 
of the pharmacokinetics and pharmacodynamics of CP.'O, ' systolic and 
diastolic blood pressure and heart rate(HR); mean blood pressure(MAP) 
, echo parameters: end-diastolic diameter (EDD), end-systolic diameter 
(ESD), percent fractional shortening (%FS), end-diastolic volume (EDV) 
and end-systolic volume (ESV),Percent ejection fraction (%EF),systemi 
vascular resistance (SVR) 
Study Design double-blind, crossover, placebo-controlled 
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Country  Italy 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Gordon 1995 
Study Title Creatine supplementation in chronic heart failure increases skeletal 
muscle creatine phosphate and muscle performance.(174) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Male patients with heart failure (HF) aged 43-70 years, ejection fraction 
(EF) < without intermittent claudication, diabetes mellitus, chronic 
obstructive pulmonary disease, neurologic disease or any other disease 
which may limit physical performance other than heart failure 
,exertional Angina, significant valvular heart disease as estimated by 
Doppler echocardiography. All patients were medicated with diuretics, 
angiotensin-converting enzyme inhibitors, digoxin, beta-receptor 
blockers, amiodarone and on warfarin 
Intervention creatine supplementation(with glucose) for 1 week  
Comparison placebo (glucose) for 1 week 
Outcome Knee extensor exercise, Two-legged cycle ergometry (heart rate and 
blood Pressure and working capacity) were measured, Unilateral 
concentric knee extensor performance and Skeletal muscle biopsies. 
Metabolites: muscle total creatine and phosphocreatine and creatine. 
Radionuclide angiography at rest and during exercise 
Study Design Parallel randomised Control Trial 
Country  Sweden 
COI disclosed No 
Financial sponsor  disclosed Yes 
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Name of Financial sponsor Swedish Medical Research Council (4494 and 9515), the Swedish Heart 
and Lung Foundation and the Salus 60-year Medical Foundation. 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Grazioli 1992 
Study Title Multicenter controlled study of creatine phosphate in the treatment of 
heart failure.(175) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population patients hospitalised for heart failure;  
Intervention One gram CrP intravenously  daily added to conventional treatment or 
no added treatment for two weeks (acute treatment) followed by 500 
mg CrP intramascularly daily or no added treatment for 1 month 
Comparison Conventional treatment 
Outcome Dyspnea, pulmonary stasis, peripheral edema and angina were 
measured before and after 15 and 45 days of treatment.  
Electrocardiogram (ECG) performed before and after 15 days of 
treatment to assess variations in rhythm, type and number of 
premature beats, ST segment, T wave, and atrioventricular conduction 
Study Design Parallel randomised Control Trial 
Country  Italy 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  




Study Title Creatine supplementation improves muscle strength in patients with 
congestive heart failure 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Patients with a history of congestive heart failure of more than 6 
months, NYHA II and III, and a peak oxygen uptake (peak VO2) of less 
than 20 ml/min/kg be free from diseases limiting physical performance 
other than heart failure, e.g. peripheral artery disease. 
Intervention  5 g creatine, four times daily. After 6 weeks patients were crossed over 
to the placebo group. 
Comparison Placebo, four times daily. After 6 weeks patients were crossed over to 
creatine group (5 g creatine) 
Outcome At baseline, after 6, and after 12 weeks,  
Cardiopulmonary exercise tests: Oxygen uptake (VO2), carbon dioxide 
output (VCO2), instantaneous expiratory gas concentration throughout 
the respiratory cycle, and minute ventilation (VE), Peak oxygen uptake 
(Peak VO2 ) . 
Six minute walk test: dyspnea, Minnesota living with heart failure 
questionnaire, Elbow flexor muscle strength and Echocardiography 
Study Design Cross over Randomised Control Trial 
Country  Germany 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Ruda 1988 
Study Title Reduction of ventricular arrhythmias by phosphocreatine (Neoton) in 
patients with acute myocardial infarction(177) 
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Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Patients aged 35 to 70 years(mean 56.0 f 1.5)  with acute myocardial 
infaction  (AMI) admitted to the coronary care unit within 6 hours of 
the onset of chest pain.  
Intervention CrP 2 g bolus injection followed by 2-hour infusion at the rate of 4g/h, a 
total of 10 gram. Patients also received morphine for pain relief  
Comparison  Sodium chloride isotonic solution according to the PCr administration 
regimen. Patients also received morphine for pain relief  
Outcome Multiform ventricular premature beats (VPBs), Heart rate, Ventricular 
premature beats, ventricular arrhythmias, Ventricular tachycardia, 
Ventricular fibrillation. Complications/side  
Study Design Parallel randomised Control Trial 
Country  Russia 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
  
Cochrane Review title (Accession number): Cinnamon for diabetes mellitus (CD007170) (108) 
Akilen 2010 
Study Title Glycated haemoglobin and blood pressure-lowering effect of cinnamon 
in multi-ethnic type 2 diabetic patients in the UK: a randomized, 
placebo-controlled, double-blind clinical trial. (137) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Adults; aged ≥ 18 years; diagnosed with type 2 diabetes mellitus on two 
consecutive FPG measurements of greater than 7 mmol⁄ l; an HbA1c ‡ 
7%;treated with oral hypoglycaemic agents.  
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Intervention oral, cinnamon (C. cassia) capsule, 500 mg (1 x 500 mg) with breakfast, 
1000 mg (2 x 500 mg) with lunch and 500 mg (1 x 500 mg) with dinner 
for 12 weeks 
Comparison oral, starch capsule, 500 mg (1 x 500 mg) with breakfast, 1000 mg (2 x 
500 mg) with lunch and 500 mg (1 x 500 mg) with dinner for 12 weeks 
Outcome Height, weight and waist circumference (anthropometrics) were 
measured at baseline (week 0) and post-intervention (week 12) and 
BMI was calculated accordingly HbA1c; diastolic and systolic blood 
pressure; total cholesterol; low-density lipoprotein cholesterol; high-
density lipoprotein cholesterol; triglycerides; FBGL; total energy intake; 
BMI 
Study Design Parallel randomised Control Trial 
Country  United Kingdom 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Thames Valley University UK; Jeffrey Kelson Diabetes and Endocrine 
Centre, Central Middlesex Hospital London; Brent NHS London; 
Department of Dietetics, Brent National Health Services, London; 
Research and Development Office, 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Altschuler 2007 
Study Title The effect of cinnamon on A1c among adolescents with type 1 
diabetes.(138) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Male and female adolescents aged 13 to 18 years diagnosed with type 
1 diabetes mellitus > 18 months duration; presentation to the clinic for 
routine care, no hospital admissions for medical or psychiatric reasons 
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in the 12 months before enrollment, ability to be accessed by phone 
and not pregnant. 
Intervention oral, cinnamon 1000 mg tablet, daily for 12 weeks 
Comparison oral, lactose tablet, daily for 12 weeks 
Outcome Primary outcome(s) HbA1c , daily insulin intake, adverse events, insulin 
sensitivity 
Study Design Parallel randomised Control Trial 
Country  United States of America 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Kaminsky Family Fund, the President’sOffice,and the Senior Fellows 
program at Dartmouth College 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Unfavourable to financial sponsor 
  
Blevins 2007 
Study Title Effect of cinnamon on glucose and lipid levels in non-insulin-dependent 
type 2 diabetes.(139) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Male and female participants with type 2 diabetes mellitus; no age limit 
Exclusion criteria: insulin use; cinnamon supplementation; HbA1c 
<6.0%; acute illness Diagnostic criteria: American Diabetes Association 
(2003) criteria Co-morbidities: not stated Co-medications: oral 
hypoglycaemic agents (metformin; thiazolidinediones); HMGCoA 
reductase inhibitors duration of diabetes 
Intervention oral, cinnamon (C. cassia) 500 mg capsule, twice a day for 3 months (12 
weeks) 
Comparison oral, wheat flour capsule, twice a day, for 3 months (12 weeks) 
Outcome HbA1c measured at baseline and three months follow up 
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FBGL, serum cholesterol triglyceride, serum insulin; BMI measured at 
1,2 and 3 months follow up. 
Study Design Parallel randomised Control Trial 
Country  United states of America 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor National Center for Research Resources, National Institutes of Health.  
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Unfavourable to financial sponsor 
  
Crawford 2009 
Study Title Effectiveness of cinnamon for lowering hemglobin A1c in patients with 
type 2 diabetes: a randomised, controlled trial(140) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Patients ≥ 18 years were recruited from the population served by the 
96th Medical Group, Eglin Air Force Base,Florida.  Patients were eligible 
if they were included in the Population Health database as patients 
with diabetes (International Classification of Diseases, 9th revision, 
code for diabetes), had an HbA1c of _7.0% on a laboratory blood draw 
during the last 6 months.  
Intervention Oral, 2 x 500 mg cinnamon (C. cassia) capsules, daily , 90 days (12.9 
weeks).Co-interventions: food and normal medication 
Comparison Usual care, 90 days (12.9 weeks). Co-interventions: food and normal 
medication 
Outcome HbA1C at baseline and end of follow up   
Study Design Parallel randomised Control Trial 
Country  United states of America 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
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Name of Financial sponsor United States Air Force Surgeon General’s Office for Population Health 
Research 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Khan 2003 
Study Title Cinnamon improves glucose and lipids of people with type 2 
diabetes(142) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Men and women with type 2 diabetes age >40 years, not on insulin 
therapy, not taking medicine for other health conditions, and fasting 
blood glucose levels between 7.8 and 22.2 mmol/l (140–400 mg/dl). 
Intervention (route, total dose/day, frequency): oral, 1 g (2 x 500 mg), 3 g (6 x 500 
mg) or 6 g (12 x 500 mg) cinnamon (C. cassia) capsules, daily (3 groups) 
for 40 days (5.7 weeks). Co-intervention: sulfonylurea drugs, i.e., 
glibenclamide; medications did not change during the study. 
Comparison Placebo ;( route, total dose/day, frequency): oral, 2, 6 or 12 wheat flour 
capsules, daily (3 groups) for 40 days (5.7 weeks). Co-intervention: 
sulfonylurea drugs, i.e., glibenclamide; medications did not change 
during the study. 
Outcome On days 0, 20, 40, and 60 FBGL; fasting serum triglyceride; fasting 
serum cholesterol; fasting serum high-density lipoprotein cholesterol; 
fasting serum low-density lipoprotein cholesterol, VLDL, and LDL 
Study Design Parallel randomised Control Trial 
Country  Pakistan 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor partly funded by University Grants Commission/NWFP Agricultural 
University, Peshawar, Pakistan 




ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Khan 2010 
Study Title Cinnamon may reduce glucose, lipid and cholesterol level in type 2 
diabetic individuals(141) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Male and female diabetic patients , age≤40 years, with blood sugar 
levels ≥ 125 mg/dl, and not on insulin therapy 
Intervention Intervention (route, total dose/day, frequency): oral, 1.5 g (3 x 500 mg) 
cinnamon capsules, daily for 30 days  
Comparison Control (route, total dose/day, frequency): oral, 1.5 g (3 x 500 mg) 
maize flour capsules, daily for 30 days  
Outcome FBGL; fasting serum triglycerides; fasting serum cholesterol; fasting 
serum high-density lipoprotein cholesterol; fasting serum low-density 
lipoprotein cholesterol at day 0 and day 30 
Study Design Parallel randomised Control Trial 
Country  Pakistan 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Mang 2006 
Study Title Effects of a cinnamon extract on plasma glucose, HbA1c, and serum 
lipids in diabetes mellitus type 2(143) 
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Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Patients diagnosed with diabetes mellitus type 2 .Only patients treated 
with oral ant diabetics or diet were included in the study. 
Intervention  (route, total dose/day, frequency): oral, cinnamon (aqueous extract of 
C.cassia) 1000 mg capsule, 3 times a day for 4 months (16 weeks) 
Comparison (route, total dose/day, frequency): oral, 1 microcrystalline cellulose 
(placebo) capsule, 3 times a day for 4 months (16 weeks) 
Outcome HbA1c; FBGL; total cholesterol; low-density lipoprotein cholesterol; 
high-density lipoprotein cholesterol; triacylglycerol measured at 
baseline and 4 months follow up 
Study Design Parallel randomised Control Trial 
Country  Germany 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Truw Arzneimittel GmbH (Gütersloh, Germany) and Finzelberg GmbH & 
Co. KG (Andernach, Germany) 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Rosado 2010 
Study Title A Study to Determine the Effects of Cinnamon on Blood Glucose and 
Lipid Levels in Persons with type-2 Diabetes [dissertation] (136) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Participants: Male and females aged  30 to 70 years; diagnosed with 
type 2 diabetes mellitus; taking metformin for glucose control for at 
least 3 months (at a daily dose of at least 1000 mg); and FBGL 7 0 to 
16.7 mmol/L or HbA1c > 7%, with or without hyperlipidemia 
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Intervention (route, total dose/day, frequency): oral, cinnamon 250 mg (water-
soluble extract of C. burmanii; Cinnulin PF®) capsule, twice a day , for 
40 days   
Comparison Placebo; Control (route, total dose/day, frequency): oral, 250 mg bran 
cereal (control) capsule, twice a day. For 40 days (5.7 weeks).               
Co-medications: metformin, hypolipidaemic agents, and any other 
prescribed medications 
Outcome HbA1c; FBGL, PPG, total cholesterol; triglycerides; low density 
lipoprotein cholesterol; high-density lipoprotein cholesterol 
Co-medications: metformin, hypolipidaemic agents, and any other 
prescribed medications 
Study Design Parallel randomised Control Trial 
Country  Unites States of America 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Trippler Army Medical Center, Intergrity Nutreceuticals International 
and US Department of Agriculture 
Author-financial sponsor 
ties  disclosed 
Yes 
Name of Author-financial 
sponsor ties   
Rosado received ARCS foundation financial award, Soroptimist 
international foundation, US Army CORPS assosiaciton and Dr Hans and 
Clara Zimmerman foundation 




Study Title The effect of cinnamon cassia powder in type 2 diabetes mellitus(144) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Males and females, aged 30 to 70 years; diagnosed with type 2 diabetes 
mellitus (FBGL 120 to 180 mg/dL (6. 67 to 10.0 mmol/L); HbA1c > 7%); 
maintained a fixed dose of hypoglycaemic medication over the past 3 
months; 
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Intervention Oral, cinnamon (C. cassia) 1500 mg capsule, 3 times a day for 4 months 
(16 weeks) 
Comparison Oral, 1 placebo capsule, 3 times a day for 4 months (16 weeks) 
Outcome HbA1c; FBGL; total cholesterol; triglyceride; high-density lipoprotein 
cholesterol; creatinine; serum glutamic oxaloacetic transaminase; 
serum glutamic pyruvic transaminase; blood urea nitrogen; body 
weight; blood pressure measured at baseline and at 4 months follow-
up 
Study Design Parallel randomised Control Trial 
Country  Thailand 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Vanschoonbeek 2006 
Study Title Cinnamon supplementation does not improve glycemic control in 
postmenopausal type 2 diabetes patients(145) 
Non-communicable disease Diabetes 
Nutrition-related risk factor NA 
Population Postmenopausal women  diagnosed with type 2 diabetes mellitus 
Intervention oral, cinnamon 500 mg (C. cassia) capsule, 3 times a day for 6 weeks 
Comparison oral, 1 wheat flour capsule, 3 times a day for 6 weeks 
Outcome HbA1c; FBGL; fasting plasma insulin; OGIS; ISIcomp; HOMA-IR; total 
cholesterol; low-density lipoprotein cholesterol; high-density 
lipoprotein cholesterol; triacylglycerol tests before and after follow up  
Study Design Parallel randomised Control Trial 
Country  Netherlands 
COI disclosed No 
Financial sponsor  disclosed No 
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Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
  
Cochrane Review title (Accession number): Garlic for the prevention of cardiovascular morbidity and 
mortality in hypertensive patients (CD007653) (85) 
Auer 1990  
Study Title Hypertension and hyperlipidaemia: garlic helps in mild cases(178) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Non-hospitalized patients, recruited from general practices, with mild 
hypertension (WHO stage I and II, diastolic pressure between 95-104 
mmHg on “two control measurements with 14 days between each. 
Intervention Fourteen days of “acclimatisation” then followed by active treatment 
100mg each garlic powered preparation three times daily for 12 weeks  
Comparison 14 days of“acclimatization” followed by two  capsules  of a similar 
looking placebo three times daily for 12 weeks  
Outcome Pulse, triglycerides, total cholesterol, supine/standing systolic and 
diastolic blood pressure, aspartate aminotransferase, alanine 
aminotransferase, gamma glutamyl transpeptidase, and blood sugar, 
serum glutamate pyruvate transfarase, serum glutamate oxaloacetate 
transaminase, and blood sugar at week 0,4,8 and 12. 
Study Design Multicentre randomised Control Trial 
Country  Germany 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
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Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Cochrane Review title (Accession number):  Coenzyme Q10 for heart failure  (CD008684) (89) 
Adarsh 2008 
Study Title Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in 
hypertrophic cardiomyopathy (HCM)(162) 
Non-communicable disease Cardiovascular Diseases 
Nutrition-related risk factor NA 
Population Men and women ages 24 to 75 years, with hypertrophic 
cardiomyopathy (HCM) diagnosed clinically and by echocardiography 
and  NYHA II class of Heart Failure with symptoms of 
palpitation/dyspnea /chest pain and /or presyncope /syncope and 
echocardiographic proven diagnosis were taken up for the study. 
Intervention 100 mg of coQ10 twice daily in addition to conventional therapy for 12 
weeks  
Comparison Conventional treatment without CoQ10 for 12 weeks 
Outcome Symptoms improvement (NYHA classification) Quality of life on detailed 
questionnaire and on 6-minute walk test Mortality Improvement in 
diastolic dysfunction Improvement in mitral regurgitation Reduction in 
LVOT gradient in obstructive cases 
Study Design Non Randomised Control Trial  
Country  India 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Berman 2004 
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Study Title Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac 
transplantation: a randomized, placebo-controlled study(163) 
Non-communicable disease Cardiovascular Diseases 
Nutrition-related risk factor NA 
Population Men and women patients aged> 18 years, with end-stage heart failure 
awaiting heart transplantation. Inclusion criteria were NYHA functional 
class 3 or 4, left ventricular ejection fraction < 25%, cardiopulmonary 
exercise test (CARPET) with maximal O2 consumption < 14 ml/kg/h, and 
evident symptoms of heart failure such as nocturia, dyspnea, and 
paroxysmal nocturnal dyspnea.  
Intervention Ultrasome™—CoQ10 (special preparation to increase intestinal 
absorption) twice daily for 3 months 
Comparison Corn flour-based placebo for three months  
Outcome Symptoms improvement (NYHA classification) ,symptoms improvement 
measured on the Minnesota Living with Heart Failure Questionnaire, 
Quality of life on 6-minute walk test ,Blood tests for atrial natriuretic 
factor (ANP) and alpha Tumor necrosis factor alpha (TNF), 
Echocardiography. Six weeks into the trial, CoQ10 blood levels were 
measured to assess absorption and compliance 
Study Design Parallel randomised Control Trial 
Country  Israel 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Keogh 2003 
Study Title Randomised double-blind, placebo controlled trial of coenzyme Q10 
therapy in class II and III systolic heart failure.(164) 
Non-communicable disease Cardiovascular Diseases 
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Nutrition-related risk factor NA 
Population Patients aged 18 to 80 years with NYHA class II or III heart failure 
Patients were and had Class II or III heart failure symptoms due to 
ischaemic, valvular or idiopathic dilated cardiomyopathy with left 
ventricular systolic impairment (ejection fraction < 0.4). 
Intervention 150 mg/day coenzyme Q10 (3 divided doses); low-fat dietary advice 
with conventional medicine 
Comparison placebo (3 divided doses); low-fat dietary advice with conventional 
medicine 
Outcome Symptom class by NYHA and SAS Exercise tolerance by a 6-minute walk 
test Walk test and treadmill exercise test (modified Naughton stress 
test) assessment for clinical outcomes of heart failure Plasma levels of 
coenzyme Q10, Assessment for the clinical outcomes of heart failure 
including readmission, transplantation or death, serum creatinine, 
sodium and potassium 
Study Design Parallel randomised Control Trial 
Country  Australia 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Blackmores Ltd, Balgowlah, Sydney, and Pharma Nord, Denmark 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Khatta 2000 
Study Title The effect of coenzyme Q10 in patients with congestive heart 
failure(165) 
Non-communicable disease Cardiovascular Diseases 
Nutrition-related risk factor NA 
Population Adults patients ages > 18 years with congestive heart failure with NYHA 
class III and IV symptoms. 
Intervention 200 mg/day of CoQ10 for a period of 6 months  
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Comparison Placebo for a period of 6 months  
Outcome  Baseline and after 6 weeks: a graded symptom-limited 
cardiopulmonary exercise test using the Naughton protocol, 
Radionuclide ventriculography was performed by using standard 
techniques and Serum concentration of coenzyme Q10 was 
measured. 
Study Design Parallel randomised Control Trial 
Country  United States of America 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor grant P60AG12583 from the National Institute of Aging, Claude D. 
Pepper Older Americans Independence Center, Bethesda, Maryland 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Unfavourable to financial sponsor 
  
Kocharian 2009 
Study Title Coenzyme Q10 improves diastolic function in children with idiopathic 
dilated cardiomyopathy.(166) 
Non-communicable disease Cardiovascular Diseases 
Nutrition-related risk factor NA 
Population Patients younger than 18 years with a complete profile as a known case 
of idiopathic dilated cardiomyopathy according to the definition of 
World Health Organization classification with stability of at least 1 
month in medications, received for treatment of cardiac failure and 
with presence of a normal sinus rhythm. 
Intervention coenzyme Q10 2 mg/kg/day in 2 or 3 divided doses, these being 
increased to the maximum dose of 10 mg/kg/day according to 
tolerance or the appearance of side effects with conventional medicine 
Comparison placebo in 2 or 3 divided doses per day with conventional medicine 
Outcome Left ventricular ejection fraction 
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Study Design Parallel randomised Control Trial 
Country  Iran 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Morisco 1993 
Study Title Effect of coenzyme Q10 therapy in patients with congestive heart 
failure: a long-term multicenter randomized study(167) 
Non-communicable disease Cardiovascular Diseases 
Nutrition-related risk factor NA 
Population Adults Patients ages > 18 years with NYHA III or IV heart failure  
Patients affected by severe congestive heart failure, as assessed by 
history of heart disease with symptoms of dyspnea or fatigue or both 
together with signs of fluid retention, and no evidence of primary 
pulmonary disease. 
Intervention coenzyme Q10 50 mg twice or 3 times daily 
Comparison Placebo twice or 3 times daily 
Outcome NYHA clinical status Incidence of severe cardiovascular complications 
(pulmonary oedema, cardiac asthma, arrhythmia), Length of 
hospitalisation 
Study Design Multicenter randomised Control Trial 
Country  Italy 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Associazione Italiana per la Ricerca in Medicina Interna (AIRMI) 
Author-financial sponsor 
ties  disclosed 
No 
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Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Munkholm 1999 
Study Title Coenzyme Q10 treatment in serious heart failure(168) 
Non-communicable disease Cardiovascular Diseases 
Nutrition-related risk factor NA 
Population Adults > 18 years with NYHA II or III heart failure with stable heart 
values of LVIDD and LVEF on two echocardiographic examinations 
spaced 3 months apart differed by less than 5%, and unchanged 
medication in that period. 
Intervention coenzyme Q10 in soya oil 100 mg twice daily  for 12 weeks  
Comparison placebo-capsules containing only soya oil ,twice daily for 12 weeks 
Outcome Baseline and post-therapeutic serum levels of coenzyme Q10 ,Left 
ventricular ejection fraction and NYHA clinical status 
Study Design Parallel randomised Control Trial 
Country  Denmark 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
  
Cochrane Review title (Accession number): Dietary flavonoid for preventing colorectal neoplasms 
(CD009350) (32) 
Akhter 2008 
Study Title Dietary Soy and Isoflavone Intake and Risk of Colorectal Cancer in the 
Japan Public Health Center Based Prospective Study.(128) 
Non-communicable disease Cancer 
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Nutrition-related risk factor NA 
Population Japanese nationals ages 45 -74 years visiting public health centres.  
Intervention (Exposure) Dietary soy and isoflavone intake 
Comparison NA 
Outcome Association of isoflavone intake with CRC risk and Adjusted for age, 
public health centre area, history of diabetes mellitus, BMI, leisure time 
physical activity, smoking, alcohol, intake of vitamin D, dairy products, 
meat, vegetable, fruit, and fish, also adjusted for menopausal status 
and current use of female hormones in women 
Study Design Prospective Cohort Study 
Country  Japan 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Grant-in-Aid for Cancer Research and for the Third-term 
Comprehensive 10-year Strategy for Cancer Control from the Ministry 
of Health, Labor and Welfare of Japan. 
Author-financial sponsor 
ties  disclosed 
Yes 
Name of Author-financial 
sponsor ties   
M Akhter received a Research Resident Fellowship from the Foundation 
forPromotion of Cancer Research (Japan) for the Third-term 
Comprehensive 10-Year-Strategy for Cancer Control. 
Author’s conclusions Unfavourable to financial sponsor and author-financial sponsor ties 
  
Akhter 2009 
Study Title Dietary isoflavone and the risk of colorectal adenoma: a case-control 
study in Japan(129) 
Non-communicable disease Cancer 
Nutrition-related risk factor NA 
Population Men aged 50–79 years or women aged 40–79 years who underwent 
total colonoscopy from the anus to the caecum.  
Intervention (Exposure) Isoflavone intake 
Comparison NA 
Outcome Association of isoflavone intake with CRC risk adjusted for age, public 
health centre area, history of diabetes mellitus, BMI, leisure time 
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physical activity , smoking, alcohol, intake of vitamin D, dairy products, 
meat, vegetable, fruit, and fish, also adjusted for menopausal status 
and current use of female hormones in women 
Study Design Case control Study 
Country  Japan 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Comprehensive 10-year Strategy for Cancer Control from the Ministry 
of Grants-in-Aid for Cancer Research (17-9) and for the Third Term 
Comprehensive 10-year Strategy for Cancer Control from the Ministry 
of Health, Labor and Welfare of Japan, and by Grants-in-Aid for 
Scientific Research on Priority Areas (17015049) and for Young 
Scientists (A-19689014) from the Ministry of Education, Culture, Sports, 
Science and Technology of Japan. 
Author-financial sponsor 
ties  disclosed 
Yes 
Name of Author-financial 
sponsor ties   
M Akhter received a Research Resident Fellowship from the Foundation 
for Promotion of Cancer Research (Japan) for the Third-term 
Comprehensive 10-year Strategy for Cancer Control. 
Author’s conclusions Favourable to financial sponsor and author-financial sponsor ties 
  
Bobe 2008 
Study Title Dietary flavonoids and colorectal adenoma recurrence in the Polyp 
Prevention Trial(130) 
Non-communicable disease Cancer 
Nutrition-related risk factor NA 
Population Participants at least 35 years of age and have had at least one histologic 
confirmed colorectal adenoma identified in six months before study 
entry (I = 958, C = 947); had to be within 150% of their recommended 
weight, without a history of inflammatory bowel disease, bowel 
resection, adenomatous polyposis syndrome, or prior history of 
adenomas or CRC, and not currently using lipid-lowering medications 
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Intervention Intake of total flavonoids, 6 major flavonoid subgroups, and 29 
individual flavonoids by intake of low-fat high-fiber, high-fruit, and 
high-vegetable diet 
Comparison NA 
Outcome Association of total flavonoids and six main flavonoid subgroups intake 
with adenoma recurrence 
Adjusted for age, sex, BMI, dietary fibre consumption, and regular 
NSAID use. 
Study Design Randomized, multicenter trial  
Country  United States of America 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Intramural Research Program, National Cancer Institute, NIH, Bethesda, 
MD 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Cutler 2008 
Study Title Dietary flavonoid intake and risk of cancer in postmenopausal women: 
the Iowa Women’s Health Study(131) 
Non-communicable disease Cancer 
Nutrition-related risk factor NA 
Population Post-menopausal women, aged between 55-69 years randomly 
selected 
Intervention (Exposure) Flavonoid intake   
Comparison NA 
Outcome Association of total flavonoids and seven flavonoid subclasses with 
lung, colorectal, breast, pancreatic and upper aerodigestive cancer risk 
among postmenopausal women. Adjusted for age, energy intake , 
education level, race, BMI, multivitamin use, activity, smoking history 
and pack years 
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Study Design Prospective Cohort study 
Country  United States of America 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor National Cancer Institute and International Life Sciences Institute (ILSI) 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Lin 2006 
Study Title Flavonoid intake and colorectal cancer risk in men and women (132) 
Non-communicable disease Cancer 
Nutrition-related risk factor NA 
Population Female registered nurses aged 30–55 years from 11 US states and US 
male dentists, podiatrists, pharmacists, optometrists, osteopaths and 
veterinarians aged 40–75 years were enrolled. 
Intervention(exposure) Total intake and intake of individual flavonoids 
Comparison NA 
Outcome Association of total flavonoids and three flavonoid subclasses intake 
with CRC risk adjusted for age, BMI, family history of CRC, history of 
colorectal polyps, prior sigmoidoscopy screening, physical activity, 
smoking, red meat intake, alcohol , total energy, calcium, folate and 
fibre intake, aspirin and multivitamin use, and postmenopausal 
hormone replacement therapy in women 
Study Design Prospective Cohort Study 
Country  United States of America 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
Name of Financial sponsor National Institutes of Health and National Colorectal Cancer Research 
Alliance 




ties  disclosed 
Yes Dr. Jennifer 
Lin is a recipient of a National Cancer Institute Career 
Development Award (KCA112529). 
Name of Author-financial 
sponsor ties   
National Cancer Institute Career Development Award (KCA112529). 
Author’s conclusions Unfavourable to financial sponsor and author-financial sponsor ties 
  
Simons 2009 
Study Title Dietary flavonol, flavone and catechin intake and risk of colorectal 
cancer in the Netherlands Cohort Study(133). 
Non-communicable disease Cancer 
Nutrition-related risk factor NA 
Population  Men and women aged 55–69 years  
Intervention (Exposure) Intake of total flavonoids and three flavonoid subclasses 
Comparison NA 
Outcome Association of flavonol, flavone and catechin intake with CRC risk 
Adjusted for age, family history ofCRC, smoking, alcohol, occupational 
physical activity at longest held job, BMI and processed meat intake 
Study Design Prospective Cohort Study 
Country  Netherlands 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Dutch Cancer Society, Netherlands Organization for Scientific Research–
Earth and Life Sciences (NWO-ALW) (VENI Innovational Research Grant 
to ICWA). 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Unfavourable to financial sponsors 
  
Theodoratou 2007 
Study Title Dietary flavonoids and the risk of colorectal cancer(134) 
Non-communicable disease Cancer 
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Nutrition-related risk factor NA 
Population Men and women aged 16 to 79 years with  incident cases of 
adenocarcinoma of colon or rectum in patients presenting to surgical 
units in Scottish hospitals 
Exposure Dietary flavonoids intake  
Comparison NA 
Outcome Association of six main flavonoid subclasses intake with CRC risk 
Adjusted for family history of CRC, total energy intake, total fibre 
intake, alcohol intake, NSAID intake, smoking, BMI, physical activity  
mutually between flavonoid categories 
Study Design Case control Study 
Country  Scotland 
COI disclosed No 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Medical Research Council, Chief Scientist Office, and Cancer Research 
UK 
Author-financial sponsor 
ties  disclosed 
Yes 
Name of Author-financial 
sponsor ties   
Medical Research Council, Chief Scientist Office, and Cancer Research 
UK,(M. Dunlop, H. Campbell, and M. Porteous) and Greek State 
Scholarship Foundation, studentship (E. Theodoratou). 
Author’s conclusions Favourable to financial sponsor and author-financial sponsor ties 
  
Wang 2009 
Study Title Dietary intake of selected flavonols, flavones, and flavonoid-rich foods 
and risk of cancer in middle-aged and older women(135) 
Non-communicable disease Cancer 
Nutrition-related risk factor NA 
Population Women aged ≥ 45 years  
Intervention (Exposure) Intake of selected flavonoids and flavonoid-rich foods 
Comparison NA 
Outcome Association of flavonoids intake with breast, colorectal, lung, 
endometrial and ovarian cancer risk Adjusted for smoking , alcohol, 
physical activity, postmenopausal status, hormone replacement 
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therapy use, multivitamin use, BMI, family history of CRC, ovary cancer, 
and breast cancer, intake of fruit and vegetables, fibre, folate and 
saturated fat, and history of benign colorectal polyps 
Study Design Prospective Cohort Study 
Country  United States of America 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
Name of Financial sponsor National Institutes of Health, Bethesda, MD, Research Scholar Grant 
from the American Cancer Society and US Department of Agriculture 
Research Service. 
Author-financial sponsor 
ties  disclosed 
Yes 
Name of Author-financial 
sponsor ties   
MD; a Research Scholar 
Grant from the American Cancer Society; and US Department of 
Agriculture. Research Service under Cooperative Agreement no. 58-
1950-4-401 
Author’s conclusions Unfavourable to financial sponsor and author-financial sponsor ties 
  
Cochrane Review title (Accession number): Co-enzyme Q10 supplementation for the primary 
prevention of cardiovascular disease (CD010405) (96) 
Bargossi 1994 
Study Title Exogenous CoQ10 supplementation prevents plasma ubiquinone 
reduction induced by HMG-CoA reductase inhibitors(169) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population 34 outpatients with primary hypercholesterolaemia (LDL-cholesterol > 
190 mg/dl, triglycerides < 200 mg/dl, 5 ° percentile < HDL-cholesterol < 
95 ° percentile of a reference population recruited in Italy 
Intervention Drug-free controlled diet period followed by (statin + CoQ10): 
simvastatin (20 mg/day) plus CoQ10 (100 mg/day) for 3 months, 
followed by crossover to control  
Comparison Drug-free controlled diet period followed by Control (statin): 
simvastatin (20 mg/day) for 3 months After this first 3-month (90-day) 
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phase the 2 groups were crossed over followed by crossover to 
intervention  
Outcome Blood pressure, total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglycerides 
Study Design Cross over Randomised Control Trial 
Country  Italy 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Kaikkonen 2000 
Study Title Antioxidative efficacy of parallel and combined supplementation with 
coenzyme Q10 and d-α-tocopherol in mildly hypercholesterolemic 
subjects: a randomised placebo controlled clinical study(170) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Men and postmenopausal women, aged 60.7±5.7 years, with body 
mass index 26.9 :k 3.6 kg/m 2 (mean + SD), mild hypercholesterolemia 
(serum cholesterol 5.90 i 0.96 mmol/1, mean ± SD) and a regular HMG-
CoA reductase inhibitor treatment. 
Intervention Intervention (CoQ10): Soy bean oil-based CoQ10 (2 x 100 mg daily) for 
3 months. 2 capsules in the morning and 2 in the evening with meals 
Co-intervention: conventional treatments and lifestyle. 
Comparison Soybean oil capsules, 2 capsules in the morning and 2 in the evening 
with meals. Co-intervention: conventional treatments and lifestyle. 
Outcome Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides 
Study Design Parallel randomised Control Trial 
Country  Finland 
COI disclosed No 
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Financial sponsor  disclosed Yes 
Name of Financial sponsor Pharma Nord, Denmark and the Yrj6 Jahnsson Foundation, Finland. 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Unfavourable to financial sponsor 
  
Lee 2011 
Study Title Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, 
and fatigue in obese subjects: a double-blind randomised controlled 
study(171) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Obese men and women with age>20 years of age, BMI greater than 25 
kg/m2  
Intervention 200 mg CoQ10 pill once a day for 12 weeks 
Comparison placebo pill once a day for 12 weeks 
Outcome Systolic blood pressure, diastolic blood pressure, total cholesterol, HDL-
cholesterol, triglycerides 
Study Design Parallel randomised Control Trial 
Country  Korea 
COI disclosed Yes 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Mabuchi 2007 
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Study Title Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 
and liver and muscle enzyme levels in hypercholesterolemic patients 
treated with atorvastatin: a randomized double-blind study(160) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Japanese men and women with hypercholesteraemic (above 220 
mg/dL). 
Intervention 4-week dietary lead-in period (less than 300 mg/day of low cholesterol 
diet) followed by (statin + CoQ10): atorvastatin (10 mg/day) for 16 
weeks plus CoQ10 (100 mg/day) for 12 weeks with no changes to 
dietary and smoking patterns. 
Comparison 4-week dietary lead-in period (less than 300 mg/day of low cholesterol 
diet) followed by Control (statin + placebo): atorvastatin (10 mg/day) 
for 16 weeks plus placebo for 12 weeks with no changes to dietary and 
smoking patterns 
Outcome Serum total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides 
Study Design Parallel randomised Control Trial 
Country  Japan 
COI disclosed Yes 
Financial sponsor  disclosed Yes 
Name of Financial sponsor Kaneka Co. 
Author-financial sponsor 
ties  disclosed 
No check  
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions Favourable to financial sponsor 
  
Yamagami 1986 
Study Title Effect of coenzyme Q10 on essential hypertension, a double blind 
controlled study. Biomedical and Clinical Aspects of Coenzyme 
Q10(161) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
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Population Men and women with essential hypertension whose blood pressure 
was higher than 150/90 mmHg 
Intervention Lead-in period of at least 4 weeks, during which symptoms and blood 
pressure were stable followed by 3 capsules daily 33.3 mg CoQ10 daily   
Comparison Lead-in period of at least 4 weeks, during which symptoms and blood 
pressure were stable followed by 3 capsules daily of inactive placebo. 
Outcome Systolic blood pressure, diastolic blood pressure 
Study Design Parallel randomised Control Trial  
Country  Japan 
COI disclosed No 
Financial sponsor  disclosed No 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
Author’s conclusions NA 
  
Young 2007 
Study Title Effect of coenzyme Q10 supplementation on simvastatin-induced 
myalgia(172) 
Non-communicable disease Cardiovascular Disease 
Nutrition-related risk factor NA 
Population Male and female patients with previous statin-related myalgia 
Intervention 2-week washout of coenzyme Q10 supplements and lipid-modifying 
therapies, except for ezetimibe followed CoQ10 capsules (200 mg/day) 
for 12 weeks combination with upward dose titration of simvastatin 
from 10 mg/day, doubling every 4 weeks if tolerated to a maximum of 
40 mg/ day. 
Comparison 2-week washout of coenzyme Q10 supplements and lipid-modifying 
therapies followed by placebo for 12 weeks in combination with 
upward dose titration of simvastatin from 10 mg/day, doubling every 4 
weeks if tolerated to a maximum of 40 mg/day 
Outcome Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides 
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Study Design Parallel randomised Control Trial  
Country  New Zealand 
COI disclosed Yes 
Financial sponsor  disclosed National Heart Foundation of New Zealand, Auckland , New Zealand 
Name of Financial sponsor NA 
Author-financial sponsor 
ties  disclosed 
No 
Name of Author-financial 
sponsor ties   
NA 
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Table a8: Table of excluded primary studies  
 Title of Primary Study Reason for exclusion 
Pedone 
1984 
An assessment of the activity of creatine phosphate (Neoton) 
on premature ventricular beats by continuous ECG monitoring 
in patients with coronary cardiac disease. (189)  
Article was published in a 
language other than English  
Pedone 
1984-2 
Myocardial T1-201 scintigraphy in the study of the 
development of acute myocardial infarction. Evaluation of the 
effects of a drug with metabolic action: creatine phosphate. 
(190) 
Article was published in a 
language other than English 
Samarenko 
1987 
Initial experience with using phosphocreatine in patients in 
the early (up to 6 hours) period of myocardial infarction. (191) 
Article was published in a 
language other than English 
Zahorska-
Markiewicz  
Effect of chitosan in complex management of obesity. (192) Article was published in a 
language other than English 
Carmenini 
1994 
Controlled multicentric clinical study with placebo in patients 
with dilatative myocardiopathy functional class II-III N.Y.H.A. 
treated with oral phosphocreatinine. (193) 
Article was published in a 
language other than English 
Maggi 1990 Double-blind multicenter clinical trial on the efficacy of 
phosphocreatinine vs L-carnitine and placebo in a group of 
patients affected by heart disease. (194) 
Article was published in a 
language other than English 
Zochowski 
1994 
Use of phosphocreatinine in treatment of acute heart failure. 
(195) 
Article was published in a 
language other than English 
Kandadziora 
1988 
Blood pressure and lipid lowering effect of garlic preparations 
in combination with a diuretic. 196) 
Article was published in a 
language other than English 
 
Table A8 is a list of the primary studies included in Cochrane nutrition reviews addressing alternative 
nutrition supplements and the four major NCDs and their nutrition-related risk factors which did not 
meet the inclusion criteria for selecting primary studies.  The primary studies were excluded as they 
were published languages other than English. 
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Table a9: Research Gaps for Cochrane nutrition reviews addressing cancer  
Table a9 shows the detailed summary of the research gaps identified in the “implications for research” section of Cochrane nutrition reviews addressing 
cancer. The first column (NCD grouping) is the NCD grouping being addressed i.e. cancer. The second column (Domain) is the EPICOT+ Framework item i.e. 
population, intervention, comparison, outcome, study design and time frame. The third column is the research recommendation for which future research 
should address e.g. children. The number in the brackets e.g. (44, 45) is the citation of review(s) (found in the References list (Section 7)) which have made 
that particular future recommendation.  The fourth column (Example) is an example of the text from the “implications for research” section from which we 
identified the research gaps.  
 
 
NCD Grouping  Domain  Future research recommendations  Example 
Cancer  Population   Children (41,45) 
 Women (46) 
 Young people (31,45) 
 Men (31) 
 Non-Chinese population (44) 
 Individuals at risk of cancer (39) (41) (31) 
 Carers of people with cancer (45) 
 Individuals with different types of cancer (43) (42) 
 Homogeneous study populations (anticancer treatment received, 
disease stage) (41,47) (44) 
 Future trials should be RCTs 
performed in homogeneous 
study populations (e.g. with 
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 Subgroups with baseline selenium exposure levels and genetic 
factors (46) 
 
  Intervention  Supplementation 
 EPA (43) 
 Sodium selenite (50) 
 Nutritional support (45) 
 Lycopene (51) 
 Vitamin D (31) 
 Calcium (39) 
Other 
 Exclude other supportive therapies (43) 
 Different  dosage of  intervention (32,39,40,49,50) 
 Different species of intervention (32,43,46,48) 
 Objective assessment of interventions (48) 
 Intervention combined with complementary medicine (41,46) 
 Different modalities of feeding (42) 
 
 Future trials should aim for the 
intervention group to have that 
level of intake (30 to 40 mg per 
day of fibre) and preferably 
higher 49). 
  Comparison   Placebo (32,43) 
 
 There is need to conduct good 
quality large scale randomised 
controlled trials using EPA 
compared to placebo with 
different cancer types (43). 
 
  Outcomes   Survival (41,43,44) 
 Mortality (51)  
 Diagnosis of cancer (46) (51) 
 Adverse effects and/or events (41) 
 Future trials on the use of 
retinoic acid (either with or 
without other treatments like 
anti-GD2) after autologous stem 






 Safety of intervention (45) 
 Efficacy of intervention (31,44,45,48,51) 
 Quality of life (31,41) 
 PSA levels (51) 
 Preferred endpoint of Colorectal cancer (49) 
 Risk-benefit balance (39) 
 Valid definitions of outcomes (47) 
 Adopting standardised outcome measures (45) 
 
cell transplant for children with 
high-risk neuroblastoma should 
be RCTs focusing on survival, 
(late) adverse effects, and 
quality of life (41). 
 
  Study Design  Design of Primary Study 
 High quality RCTs( 32,40,43–45,51) (31,41,47–50) 
 Adequately powered and/or larger RCTs (39–41,43,45,47) 
 Explicitly explaining of trial methodology (enrolment, sequence 
generation, allocation concealment, randomisation, blinding and 
ITT analysis (44) 
 Multicenter trials (39) 
 Non-experimental cohort studies (40) 
 Observational studies (46) 
 Adopting SPIRIT guidelines (31). 
 
Reporting in Primary Study 
 Adopting the  CONSORT statement (31,43,48) 
 Standardised and consistent reporting of results (45) 
 
 There is need for a well-
designed, high methodological 
quality, randomised controlled 
trial to investigate the 
effectiveness lycopene for the 
prevention of prostate cancer 
(51). 




















  Timeframe   Long period of follow-up (40) (41) (31,49) 
 Long-term survival (44) 
 RCTs should be performed in 
homogeneous study populations 
(like stage of disease) and have a 
long-term follow-up (41) 
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Table a10: Research Gaps for Cochrane nutrition reviews addressing cardiovascular diseases 
Table a10 shows the detailed summary of the research gaps identified in the “implications for research” section of Cochrane nutrition reviews addressing 
cardiovascular diseases. The first column (NCD grouping) is the NCD grouping being addressed i.e. cardiovascular diseases. The second column (Domain) is 
the EPICOT+ Framework item i.e. population, intervention, comparison, outcome, study design and time frame. The third column is the research 
recommendation for which future research should address e.g. women. The number in the brackets e.g. (64) is the citation of review(s) (found in the 
References list (Section 7)) which have made that particular future recommendation.  The fourth column (Example) is an example of the text from the 




 Domain  Recommendation  Example 
Cardiovascul
ar Diseases 
 Population   Early stages of life (95) 
 Women (92) 
 Healthy people (35) (86) 
 Groups other than middle-aged women (13) 
 Ethnicity (75) (69) (36) 
 Gender (78) (95) 
 Older people (69,95) 
 Individuals at risk of cardiovascular diseases (12) (84) (76) 
 Individuals with hypertension (90) (77,78,85,88) (73) 
 People with PAD (63) 
 People with post-stroke dysphagia (64) 
 Populations with low calcium intake (95) 
 More placebo controlled 
trials are warranted to 
clarify whether calcium 
supplementation can 
reduce blood pressure in 
people with elevated 
blood pressure (77) 
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 Individuals with a previous cerebral haemorrhage (71)  
 Older patients (those aged over 80 years) stroke (71) 
 Individuals with acute states of COPD (66) 
 People with FH  and their care givers (70) 
 Participants across a wider range of selenium status (92) 
 Poor people (69) 
 Socially excluded people (69)  
  
  Setting   Primary care and the workplace compared with hospital settings (68) 
 population and community level (35) 
 United Kingdom healthcare and other settings (35) 
 lower and higher income countries (72) 
 low and middle-income countries (69). 
 Developing countries (69) 
 population level (e.g. workplace, institutional, regulatory) (91) 
 international setting (36) 
 
 Research in the setting in 
which dietary advice is 
given would inform us 
about the effectiveness of 
advice in primary care and 
the workplace compared 
with hospital settings (68) 
  Intervention  Food  
 Effect of cocoa (90) 
 Higher content and /or better bioavailability of the active peptides 
(87) 
 Garlic therapy (62) 
 Effects of ALA (72) 
 Dietary fish (72) 
 Dose and formulation of omega-3 fatty acid (74)  
 Ranges of selenium concentration and dietary selenium intakes (92) 
 Provision of fruit and vegetables (13) 
 Black and green tea (94) 
 Long term research to 
help us understand what 
types of unsaturated fats 
are most useful in the diet 
when replacing saturated 
fats (monounsaturated 
fats, polyunsaturated fats 
and the relevant specific 
fatty acids) are urgently 
needed. (12) 
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 Garlic Dosage (85) 
 Creatine analogues (83) 
 Isoflavones (36) 
 
 
Dietary patterns and advice 
 Low-fat dietary intervention (86) 
 Cholesterol-lowering diet (70) 
 Whole grain diets (82) 
 Low GI diets (76) 
 Elements of dietary advice (e.g. length and frequency of contact, type 
of approach (e.g. individual or group, behavioural therapy or 
instructional techniques), level of belief of practitioner, level of 
training of practitioner, patient satisfaction, initial characteristics of 
patients (68) 
 Types of unsaturated fats replacing saturated fats (12) 
 Effect of dietary interventions (88) 
 Maintenance of dietary fat modification whilst on lipid lowering 
medication (12) 
 Reduced saturated fat whilst on lipid-lowering medication (10) 
 Plausible interventions of dietary salt reduction (91) 
 Effect of dietary calcium vs supplemental version (95) 
 nurse-led dietary interventions compared with dietetic advice (68) 
 
 
Nutritional education and counselling programmes  
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 Types of self-help resources (interactive computer programmes vs 
simple leaflets (68) 
 Modality of administering self-help (leaflet handed out by a doctor vs 
nurse vs post) (68) 
 Non-individualised modes of dietary health promotion (35) 
 Weight-loss and maintenance program (84) 
 Low sodium dietary advice and reduced sodium advice (73) 
 Advice to consume more fruit and vegetables (13) 
 
Policy  
 Effects and costs of health protection (i.e.fiscaland legislative 
approaches) and primary prevention (69) 
 Effectiveness of non-individualised modes of dietary health 
promotion (35) 
 Effects of legislation ( to alter fat contents of foods, improved 
labelling, pricing initiatives and improved availability of healthier(12) 
 Voluntary and regulatory salt reduction by food industries (such as the 
UK’s reduction of salt in processed foods) (91) 
 
Supplementation 
 Potassium supplementation (alone) (80) (79) 
 Potassium &magnesium BP (80) 
 Coenzyme Q10 (89,96) 
 Calcium supplementation (77) (95) 
 Vitamin E Dosage (65) 
 Selenium supplements (92) 
 Magnesium supplementation (78) 
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 Sufficiently full details of the interventions (67) 
 Nature and duration of the intervention (93) 
 Equivalent attention and health professional time to participants (10) 
 Components of swallowing therapy (64) 
 Enhanced nutrition, anti-inflammatory nutrition supplements, 
exercise, vitamin D, anabolic agents, novel treatments such as 
selective androgen receptor modulators (SARMs), peroxisome 
proliferator-activated receptors (PPARs) agonists, neuro electric 
stimulation and specific anti-inflammatory medications (66) 
. 
 
  Comparison   Placebo (36,65,74,77–79,85) 
 Usual Care (86) 
 Vitamin E vs another treatment (65) 
 Cholesterol-lowering diet vs no dietary intervention(70) 
 Control group (95) 
 Dietary calcium vs supplemental version (95) 
 Daily calciumin take of at least 1gm in comparison with a control 
group.(95) 
 
 A three-arm or factorial 
trial comparing vitamin E 
to another treatment as 
well as to placebo would 
be useful (65) 
  Outcome   Mortality (12,65,72,73,75,82,85,88,91) 
 Morbidity (73,85,88,91,91)  
 Adverse events (74,85,88,95,96) 
 Quality of life or health related quality  of life (35,66,74,96) (64) 
 Trials utilising quality of 
life outcomes or cost-
effectiveness evaluation 
are lacking (35) 
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 Cardiovascular events (12,13,74,82,90,94,96). 
 Cardiovascular outcomes (72,76,77) 
 Cardiovascular disease risk factors (76) 
 Definition of cardiovascular events measures (36) 
 Vasoconstriction (95) 
 Number of participants who develop chest infection or pneumonia or 
who have signs of aspiration (64) 
 Blood pressure (72,77,81,91,95)  
 Long term effects on Blood pressure (80) 
 Diabetes risk (92) 
 Hormonal and lipid outcomes (91) (72,92) 
 Ankle brachial pressure index(ABI) (74) 
 Amputation rate (65) 
 Walking distance (74) 
 Time to healing (67) 
 Sustainability of behavioural change (13) 
 Skill level of staff providing care (67) 
 Need of vascular surgery (65) 
 Subjective and objective outcome measures (65) 
 Standardised outcome measures (64) 
 Legislation to modify fat (10) 
 Functional outcome (death or dependency)(64) 
 Length of inpatient stay and discharge to an institution (64) 
  
  Study 
Design 
 Design of primary studies 
 RCTs (12,13,35,62,65,66,69,70,73,75,77,79,80,85,86,88–92,94–96) 
 Multicentre trials (36,64,67,70,84,84) 
 Further large and high-
quality trials of ALA 
carried out in lower and 
higher income countries 
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 A three-arm or factorial trial (65) 
 High quality randomised controlled trials 
(6,31,35,36,64,67,68,72,76,78–80,82,84,91,125) 
 Larger trials or adequately powered (36,62,64,65,67,70,72,74,76–
78,80,82–85,91,93,95)  
 Well-designed prospective population studies (75) 
 Economic evaluation/cost effectiveness studies (10,12,35,69,96) 
 Systematic reviews (10,84) 
 Qualitative studies (69,69) 
 Random sequence generation and treatment allocation 
(64,65,67,77–79,125) 
 Blinding (64,67,78,125) 
 Attrition (64) 
 ITT analysis (65,67,78,125,125) 
 Subgroup analysis (95) 
Reporting in primary studies 
 Adopting the CONSORT statement (67) 
 
and that assess baseline 
ALA intake and use 
biomarkers to assess 
compliance would be 
helpful to clarify the 
cardiovascular effects of 
ALA. (40)  
  Time frame    Long-term trials (12,13,36,75,88,90) (35,76) (84) (73) (91). (79) (86) 
(77) (10) (74) (82,95) 
 sufficient duration of length of follow-up (62) (67) (19) 
 Long-term follow-up data (88) 
 Long-term effect of weight loss on stroke incidence (84) 
 Long enough time span to detect any long term effects on BP (80) 
 long term effects of black and green tea interventions (94) 
 
 They should enrol a large 
number of participants 
and have long enough 
follow-up to allow 
detection of any 
meaningful long-term 
effects of magnesium 
supplementation (78). 
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Table a11: Research Gaps for Cochrane nutrition reviews addressing chronic respiratory diseases 
Table a11 shows the detailed summary of the research gaps identified in the “implications for research” section of Cochrane nutrition reviews addressing 
chronic respiratory diseases. The first column (NCD grouping) is the NCD grouping being addressed i.e. chronic respiratory diseases. The second column 
(Domain) is the EPICOT+ Framework item i.e. population, intervention, comparison, outcome, study design and time frame. The third column is the 
research recommendation for which future research should address e.g. children. The number in the brackets e.g. (94-96) is the citation of review(s) (found 
in the References list (Section 7)) which have made that particular future recommendation.  The fourth column (Example) is an example of the text from the 
“implications for research” section from which we identified the research gaps 
NCD 
Grouping 




 Population   Children (57,59,60) 
 Adolescents (57) 
 Adults (59)  
 Birth and at least six years of follow up (61) 
 People with chronic asthma (52) 
 People with exercise induced bronchoconstriction/asthma (54,56) 
 Patients with different levels of asthma severity (58) 
 Habitual consumers and non-consumers of caffeine (58) 
 
 Further studies should 
examine whether weight 
reduction leads to asthma 
control in people with 
chronic asthma (52). 
  Setting   Low-income countries (e.g. Africa) (57)  There is also a need for 
these well designed studies 
in children and adolescents, 
as well as in low-income 
countries such as Africa (57) 




  Intervention  Foods 
 Caffeine ingestion (58) 
 Role of tartrazine and other food additives (55) 
 Effect of Mono and multifaceted inhalant and/or food allergen 
reduction (61) 
  
Dietary patterns and advice 
 Effects of diet and lifestyle on Asthma (52) 
 Dietary reduction of calorie intake on asthma (52) 
Dietary sodium manipulation (54) 




 Dosage and effects of Vitamin C and E (56) 
 vitamin C for exercise-induced asthma (59) 
 
 
 There is also a need for 
longer intervention as well 
as follow-up durations to 
evaluate the effect of 
sustained measures to 
achieve weight loss and to 
determine if these effects 
are still significantly present 
after a considerable period 
of time (57). 
  Comparison   Placebo (59,59) 
 placebo interventions (such as dummy mattress cvers) (61) 
 Vitamins C and E versus vitamin C alone, or versus vitamin E alone 
(56). 
 Direct head-to-head comparative trials of mono and multifaceted 
allergen reduction strategies (61) 
 
 There is also a need for 
direct head-to-head 
comparative trials of mono 
and multifaceted allergen 
reduction strategies (61) 
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  Outcome   Quality of life (30,52,56–59) 
 Exacerbation rates (30,56,59)  
 Adverse effects (56,57,59). 
 Bronchoconstriction (56,58), 
 Exercise tolerance (56) 
 Asthma symptom scores (55) 
 Impact on work and school (56) 
 Asthma symptoms/control (30,57) 
 Use of rescue medication (57),  
 Hospital utilization or admission (30,57) 
 Patients’ perception of the effect of caffeine (58)  
 Utilize guidelines for diagnosing asthma for the study outcome (61) 
adequate measurement and recording  of symptoms e.g. lung  
function,(52,55–57,59) 
 Standardised rating scales and outcome measures (53) 
 
  Future randomised placebo 
control trials should include 
the following outcomes 
robust symptom recording, 
HRQL , exacerbation rates 
and adverse effects (56) 
  Study design  Design in Primary Study 
 
 RCTs (56,57,59,61) 
 High Quality Trials (56,57,59) 
 Larger studies or adequately powered studies (30,52–56,59,60) 
 Direct head-to-head comparative trials of mono and multifaceted 
allergen reduction strategies (61) 
 Blinding and  allocation concealment (55,57) (55,61),  
 Economic evaluation/cost effectiveness studies (61)  
 
 1.Larger randomised trials 
are required in further 
research for selenium 
treatment for asthma (53) 
  Timeframe   Long term follow up (52) (57) (61) 
 Changes that persist longer than two weeks (54) 
 There is also a need for 
longer intervention as well 
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 as follow-up durations to 
evaluate the effect of 
sustained measures to 
achieve weight loss and to 
determine if these effects 
are still significantly present 
after a considerable period 
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Table a12: Research Gaps for Cochrane nutrition reviews addressing diabetes 
Table a12 shows the detailed summary of the research gaps identified in the “implications for research” section of Cochrane nutrition reviews addressing 
diabetes. The first column (NCD grouping) is the NCD grouping diabetes being addressed. The second column (Domain) is the EPICOT+ Framework item i.e. 
population, intervention, comparison, outcome, study design and time frame. The third column is the research recommendation for which future research 
should address e.g. people with type 2 diabetes. The number in the brackets e.g. (105,106) is the citation of review(s) (found in the References list (Section 
7)) which have made that particular future recommendation.  The fourth column (Example) is an example of the text from the “implications for research” 
section from which we identified the research gaps. 
NCD 
Grouping 
 Domain  Recommendation  Example 
Diabetes  Population   Children (106,108) 
 Older patients with diabetes (110) 
 People with type 2 diabetes (102,111) 
 Patients with both type 1 and type 2 diabetes (97,107,109) 
 Individuals with “normal” BP (11) 
 Individuals with early development of DKD (11) (112) 
 Participants with a higher mean baseline HbA1c greater than 8% (103) 
(121) (110) 
 Persons not currently overweight (101) 
 Genetic subgroups of the population at risk of diabetes (105) 
 
 There currently persists a 
research gap in the literature 
that investigates the effect of 
cinnamon in young children 
(108) 
  Intervention  Foods  
 Role and mechanisms of omega-3 PUFA (99) 
 Other species and parts of sweet potato (111) 
 Modality of administration of cinnamon (108) ,  
 Different cinnamon extraction and preparation (108) 
 Future research should 
explore other species of 
cinnamon and different 
parameters of 
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 Other species of cinnamon (108)  
 Whole grain foods (105) 
 
 
Dietary patterns and advice 
 Exercise with reduced energy diet (102) 
 Low-fat/high carbohydrate diet, modified-fat diet, restricted protein 
diet etc.) (102) 
 Frequency of dietary advice (102) 
 Style of dietary advice (addition of behaviour modification or not) 
(102) 
 Usual diet (unrestricted protein) versus reduction to say 0.8 g/kg/day 
(with chicken and fish instead of red meat) versus a vegetarian diet 
with no restriction in protein versus a vegetarian diet with modest 
intake (1 g/kg/day) (97) 
 More modest, sustained salt reduction (11) 
 Effect of diet plus physical activity (98) 
 Empact of low glycaemic index diets (106) 
 
Nutritional education and counselling programmes  
 Impact of individual diabetes patient education (103) 
 
Supplementation  
 Dosage of different vitamin B preparations (112) 
 
Other 
 Different treatments for Type 2 diabetes (100) 
 Novel approaches to prevent or regress retinal lesions (107) 
 Sustained interventions for weight loss (101) 
 Additional treatments for glucose control (109) 
 Explicitly 'prescribe' interventions for trials (110) 
administration, extraction 
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 Rormulation of intervention active ingredients (behaviour change 
techniques) (110) 
 Dose of intervention (frequency and intensity of interactions) (110) 
 Modality of administration of intervention (mode of delivery - 
Internet, mobile phone etc) and duration of treatment (110) 
 
  Comparison   usual diet (unrestricted protein) versus reduction to say 0.8 g/kg/day 
(with chicken (97)  
  fish instead of red meat) versus a vegetarian diet with no restriction 
in protein versus a vegetarian diet with modest intake (1 g/kg/day) 
(97) 
 individual diabetes patient education vs group education (103) 
 vitamin B compared to placebo or losartan (112) 
 
 There is a lack of evidence of 
short-term or long-term 
benefits of vitamin B 
compared to placebo or 
losartan on clinical and 
biochemical outcomes (112) 
  Outcome   mortality (102,104) 
 quality of life (97,100–102,104,106) 
 incidence of type 2 diabetes mellitus (104), 
 adverse events (106)  
 insulin resistance (104), 
 glomerular filtration rate (GFR) (97) 
 cardiovascular risk factors such e.g. lipids (97) 
 surrogate markers of kidney function (urinary albumin) (11) 
 emerging cardiovascular risk markers in type 2 diabetes (99) 
 change (or delay) in onset of anti-diabetic medication (102)  
 Reliable and validated measures of cognitive function (100) 
 long-term complications of T2DM (111) (98) 
 long-term glycaemic control (106)  
 efficacy and safety profile of vitamin B therapy (112) 
 depression, weight loss, physical activity and blood lipid profiles (110) 
 relevant intermediate endpoints for type 2 diabetes (105) 
 sustained interventions for weight loss and control (101)  
 measures of the presence and severity of neuropathy (109) 
 Outcomes should include all 
of glomerular filtration rate 
(GFR), quality of life, cost-
effectiveness and 
cardiovascular risk factors 
such as lipids (97). 




  Study 
Design 
         Design in Primary study 
 Trials (97–99,103–105,107,108,111,112) 
 High quality studies (99,103,105,108,111,112) 
 Larger number or adequately powered studies (99,103,111) 
 Economic evaluation or cost-effectiveness studies (97,101,108,110) 
 Observational trials (111)  
 Evidenced and scientific based interventions following systematic 
and scientific design (110)  
 High quality trials with (allocation concealment, minimization of 
attrition, follow-up of dropouts, comparison of dropouts to 
completers at baseline, and ITTanalysis (101). 
 
         Reporting in Primary study 
 Clarity on reporting of adverse effects (111) 
 
 In future, high quality RCTs 
are needed to establish 
efficacy and safety profile of 
vitamin B therapy especially 
treatment used in addition to 
the first line treatment (112) 
  Time Frame   Long-term studies (76)(99,105)(99,111) (97) (103) (110) 
 Long-term use dietary advice (102) 
Outcome measures that capture short- and long-term outcomes (108) 
 Long-term glycaemic control (106) 
 Short-term or long-term benefits of vitamin B compared to placebo 
or losartan (112) 
 Long-term weight loss interventions (101) 
 Studies with longer follow-up 
are needed to determine the 
long-term impact on health 
outcomes of these 
interventions and look for 
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Table a13: Research Gaps for Cochrane nutrition reviews addressing obesity and overweight 
Table a13 shows the detailed summary of the research gaps identified in the “implications for research” section of Cochrane nutrition reviews addressing 
obesity and overweight. The first column (NCD grouping) is the nutrition-related risk factor obesity and overweight being addressed. The second column 
(Domain) is the EPICOT+ Framework item i.e. population, intervention, comparison, outcome, study design and time frame. The third column is the 
research recommendation for which future research should address e.g. children aged 0-3 years. The number in the brackets e.g. (122) is the citation of 
review(s) (found in the References list (Section 7)) which have made that particular future recommendation.  The fourth column (Example) is an example of 
the text from the “implications for research” section from which we identified the research gaps. 
NCD Grouping  Domain  Recommendation  Example 
Overweight 
and Obesity 
 Population   Young children aged 0-3 years (37) 
 Children aged six to 12 years (37) 
 Adolescents (37) 
 Obese parents and their children (121) 
 Children and adolescents with obesity or overweight (117) 
 Children in preschool years and puberty (117) 
 Ethnicity, e.g. children from minority ethnic groups (121) 
 Parents in pediatric obesity intervention studies (121) 
 Overweight and obese adults (115) (33) 
 Patients and healthcare professionals (33) 
 
 More evidence is needed 
to determine effective 
interventions in young 
children, particularly those 





  Setting   Healthcare setting (33) 
 Low- and middle-income countries (33,37,117,121) 
 Faith-based settings (37)  
 We do recommend that 
further research in the 
early years and 
adolescence is conducted, 
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 Clinical setting (117) 
 
and that research should 





  Intervention  Foods 
 Detailed description of Dosage and composition of chitosan (34)  and  
green tea (116) 
 
Nutrition education and counselling programmes 
 Educational interventions other than brief face-to-face meetings (33) 
 Use of e-health systems in weight management, using distal 
measuring devices (33) 
 Use of smart phone functions in weight management (113), 
 Evidence-based (clinical) interventions (33) 
 Effectiveness of the TTM SOC (115) 
 
Dietary Patterns 
 Effects of different diet-only interventions (119) 
 Effectiveness of physical activity, dietary and other behavioural 
interventions (117) 
Other 
 Clear and detailed descriptions of the intervention(s) (115) 
 
 Further research is also 
needed into the effects of 
different diet-only 
interventions (119) 
  Comparison   New interventions to be compared to ’standard care (33) 
 
 Future studies should 
ensure that innovative 
interventions are always 
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compared to ’standard 
care’ (33) 
 
  Outcome   Adverse effects (113,116,119,121) 
 Quality of life (34,113,116,120,121) (115),  
 Morbidity (34,118)  
 Mortality (34) 
 BMI (or zBMI) (37) 
 Obesity-related comorbidities (120) 
 Risk factors for cardiovascular disease, e.g. high blood pressure, lipid, 
new diagnoses of type 2 diabetes (33) 
 Self-esteem (121),  
 Prevalence of overweight (37) 
 Mean and standard deviation for outcomes (37) 
 Effects of CrP in preventing overweight and obesity (118) 
 Activity behaviour change (120)  
 Brain-imaging techniques (117) 
 Clear and detailed descriptions of outcome measures (115) 
 Standards for measuring and reporting adherence (e.g kilograms lost 
(114) 
 
 Future studies should 
include outcomes such as 
health-related quality of 
life and adverse effects 
(116) 
  Study 
Design 
 Design of Primary Study 
 Trials (33,34,115,117,118,121) 
 Qualitative research (120) 
 Systematic review of non-randomised controlled trials (115) 
 Study designs other than randomised controlled trials (120) 
 Future studies should 
follow a standard reporting 
format, such as CONSORT 
,to ensure that all details of 
the study are available for 
assessment and  perform 
an ITT and per protocol 
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 High Quality studies (randomisation, allocation concealment, blinded 
and intention to treat analysis and power calculations) 
(33,34,115,121) 
 Large/adequately powered studies (115,117) 
 Economic Evaluation/cost effective studies (33,34,37,121) 
 (33,34,121)  
 Methods to impute missing outcome data (117) 
 ITT and per protocol (PP) analysis (116) 
 Use a protocol when conducting and reporting research (115) 
 
Reporting in Primary study 
 Adopting Consort guidelines (33,116) 
 
(PP) analysis to account for 
drop-outs after 
randomisation (116) 
  Time frame   longer-term follow-up studies (37) (117) 129) (126)(115) (114) (113) 
  
 We suggest that 
interventions and 
strategies to prevent 
obesity in children should 
include follow-up over 
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Table a14: Research gaps for Cochrane nutrition reviews addressing healthy diets 
Table a14 shows the detailed summary of the research gaps identified in the “implications for research” section of Cochrane nutrition reviews addressing 
healthy diets. The first column (NCD grouping) is the nutrition-related risk factor being addressed i.e. healthy diets. The second column (Domain) is the 
EPICOT+ Framework item i.e. population, intervention, comparison, outcome, study design and time frame. The third column is the research 
recommendation for which future research should address e.g. children aged five years and under. The number in the brackets e.g. (133) is the citation of 
review(s) (found in the References list (Section 7)) which have made that particular future recommendation.  The fourth column (Example) is an example of 




  Domain  Recommendation  Example 
Healthy 
Diets 
  Population   Children aged five years and under (123) 
 Culturally diverse backgrounds (eg. Indigenous people) 
 The investigation of the 
impact of interventions for 
children from low-income, 
minority or indigenous 
communities (including by 
subgroup analyses) (123) 
   Setting   Heath services and sports clubs (123) 
 Low-income, minority or indigenous communities (123) 
 Sports settings (122) 
 Preschools, play-groups, sports clubs, or co-operatives, (123) 
 Future interventions 
should include 
interventions implemented 
across a broader range of 
settings including heath 
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services and sports clubs 
(123) 
 
   Intervention    Different electronic modalities such as the web or mobile phones 
(123) 
 Behavioural interventions delivered by health professionals, 
telephone- or computer-based programmes (123) 
  Interventions delivered through preschools, play-groups, sports 
clubs, or co-operatives (123) 
 Clear definition and description of intervention (124) 
 Interventions with sound theoretical base which is explicitly 
reported in the publication (122) 
 Interventions that are based on logic models of change, appropriate 
theoretical frameworks and evidence (123) 
 Further studies are now 
essential to refine methods 
for providing dietary advice 
and improve diet 
adherence in the context of 
chronic diseases(124). 
   Comparison   intervention group vs control/usual care group (124) 
 adequate control group consisting of a matched sporting 
organization (122) 
 Further research with a 
comparison between an 
intervention group and a 
control/usual care group 
both providing the same 
dietary advice to capture 
the effect of the 
intervention only, without 
confounding factors is 
required (124) 
   Outcome   adverse effects (e.g. increased family grocery costs, adverse effects 
on parent self-esteem or sense of competence) (123) 
 Psychosocial, environmental determinants and  biological factors 
affecting food intake (124) 
 Future trials should 
incoperate investigation of 
potential adverse effects of 
interventions (e.g. 
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 perspectives from health professionals and clients about the 
interventions enhancing adherence (124) 
 standardized and validated self-report tools and robust objective 
measures (e.g. biomarkers) to assess adherence to dietary advice 
(124) 
 Development of policies, implementation of policies and changes in 
individual behaviour relating to the particular policy (122) 
 Use of tools validated to measure outcomes (such as sun protection 
habits, alcohol use, smoking status, frequency of healthy eating, etc) 
(122) 
 Behavior change (122) 
 
increased family grocery 
costs, or adverse effects on 
parent self esteem or sense 
of competence) as a 
routine part of intervention 
trials (123) 
   Study Design  Design of Primary study 
 High quality trials (123,124) 
 Economic evaluation/cost effective studies (123) 
 Factorial design studies (for policy interventions) (122) 
 Repeated measurements before and after design (122) 
 Further studies designed to minimise bias (124) 
 Cluster design with adequate sample size per cluster (122) 
 
 Future trials should include 
examination of the cost-
effectiveness of 
interventions found to be 
effective (123). 
   Time frame   Interventions with extended periods of follow-up (123) (124) 
 
 Further studies with a long-
term duration of more than 
12 months, and a follow-up 
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in the reference. 
Example reference style: 
Article within a journal 
Smith JJ. The world of science. Am J Sci. 1999;36:234-5. 
Article within a journal (no page numbers) 
Rohrmann S, Overvad K, Bueno-de-Mesquita HB, Jakobsen MU, Egeberg R, Tjønneland A, et al. Meat 
consumption and mortality - results from the European Prospective Investigation into Cancer and 
Nutrition. BMC Medicine. 2013;11:63. 
Article within a journal by DOI 
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. Dig J Mol Med. 
2000; doi:10.1007/s801090000086. 
Article within a journal supplement 
Frumin AM, Nussbaum J, Esposito M. Functional asplenia: demonstration of splenic activity by bone 
marrow scan. Blood 1979;59 Suppl 1:26-32. 
Book chapter, or an article within a book 
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, 
Jeon KW, editors. International review of cytology. London: Academic; 1980. p. 251-306. 
OnlineFirst chapter in a series (without a volume designation but with a DOI) 
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Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and chiral 
symmetry breaking. Top Curr Chem. 2007. doi:10.1007/128_2006_108. 
Complete book, authored 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 
3rd ed. Oxford: Blackwell Science; 1998. 
Online document 
Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal 
Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 
Jan 1999. 
Online database 
Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http://www.healthwise.org. 
Accessed 21 Sept 1998. 
Supplementary material/private homepage 
Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. Accessed 22 Feb 
2000. 
University site 
Doe, J: Title of preprint. http://www.uni-heidelberg.de/mydata.html (1999). Accessed 25 Dec 1999. 
FTP site 
Doe, J: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt (1999). Accessed 12 Nov 1999. 




ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 20 Feb 2007. 
Dataset with persistent identifier 
Zheng L-Y, Guo X-S, He B, Sun L-J, Peng Y, Dong S-S, et al. Genome data from sweet and grain 
sorghum (Sorghum bicolor). GigaScience Database. 2011. http://dx.doi.org/10.5524/100012. 
 
Figures, tables and additional files 
Preparing figures 
When preparing figures, please follow the formatting instructions below. 
 Figures should be numbered in the order they are first mentioned in the text, and uploaded 
in this order. Multi-panel figures (those with parts a, b, c, d etc.) should be submitted as a 
single composite file that contains all parts of the figure. 
 Figures should be uploaded in the correct orientation. 
 Figure titles (max 15 words) and legends (max 300 words) should be provided in the main 
manuscript, not in the graphic file. 
 Figure keys should be incorporated into the graphic, not into the legend of the figure. 
 Each figure should be closely cropped to minimize the amount of white space surrounding 
the illustration. Cropping figures improves accuracy when placing the figure in combination 
with other elements when the accepted manuscript is prepared for publication on our site. 
For more information on individual figure file formats, see our detailed instructions. 
 Individual figure files should not exceed 10 MB. If a suitable format is chosen, this file size is 
adequate for extremely high quality figures 
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Figure file types 
We accept the following file formats for figures: 
 EPS (suitable for diagrams and/or images) 
 PDF (suitable for diagrams and/or images) 
 Microsoft Word (suitable for diagrams and/or images, figures must be a single page) 
 PowerPoint (suitable for diagrams and/or images, figures must be a single page) 
 TIFF (suitable for images) 
 JPEG (suitable for photographic images, less suitable for graphical images) 
 PNG (suitable for images) 
 BMP (suitable for images) 
 CDX (ChemDraw - suitable for molecular structures) 
For information and suggestions of suitable file formats for specific figure types, please see our 
author academy. 
Figure size and resolution 
Figures are resized during publication of the final full-text and PDF versions to conform to the 
BioMed Central standard dimensions, which are detailed below. 
Figures on the web: 
 Width of 600 pixels (standard), 1200 pixels (high resolution). 
Figures in the final PDF version: 
 width of 85 mm for half page width figure 
 width of 170 mm for full page width figure 
 maximum height of 225 mm for figure and legend 
Stellenbosch University  https://scholar.sun.ac.za
164 
 
 image resolution of approximately 300 dpi (dots per inch) at the final size 
Figures should be designed such that all information, including text, is legible at these dimensions. 
All lines should be wider than 0.25 pt when constrained to standard figure widths. All fonts must be 
embedded. 
File Compression 
 Vector figures should if possible be submitted as PDF files, which are usually more compact 
than EPS files. 
 TIFF files should be saved with LZW compression, which is lossless (decreases file size 
without decreasing quality) in order to minimize upload time. 
 JPEG files should be saved at maximum quality. 
 Conversion of images between file types (especially lossy formats such as JPEG) should be 
kept to a minimum to avoid degradation of quality. 
If you have any questions or are experiencing a problem with figures, please contact the customer 
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Non-communicable diseases: burden and risk factors 
Non-communicable Diseases (NCDs) are medical conditions or diseases that are non-infectious and 
not transmissible between people (1). NCDs are commonly categorised into the following groupings: 
cardiovascular diseases, cancer (all types), chronic respiratory diseases (e.g. asthma, bronchitis), 
diabetes (type 1 and 2), renal disease, endocrine disease, neurological disorders, haematological 
disorders (e.g. sickle cell anaemia), gastroenterological disease (e.g. peptic ulcers), hepatic disease 
(e.g. liver cirrhosis), musculoskeletal disorders, skin diseases, oral diseases, genetic disorders, mental 
disorders, optometry disorders and deafness (2). The four major groups that contribute to 86% of 
deaths from NCDs are cardiovascular diseases, cancer, respiratory disease and diabetes (1). In 2012, 
NCDs accounted for 38 million deaths globally and three quarters of these deaths occurred in low- 
and middle-income countries (LMICs) (1). It is reported that the prevalence of NCDs is on the rise, 
especially in LMICs, and the World Health Organisation (WHO) predicts that by the year 2020, 300 
million people will be living with NCDs globally (8,197). The WHO recommends that governments 
and stakeholders adopt effective interventions to halt this global rise in NCDs (2).  
Risk factors associated with NCDs largely stem from unhealthy lifestyles and exposure to adverse 
physical and social environments. Modifiable risk factors include unhealthy diets, direct and passive 
smoking, other uses of tobacco, physical inactivity, excessive use of alcohol and psychological stress 
(4–7). Poor nutrition during pregnancy and childhood also predisposes individuals to develop NCDs 
later in adulthood (8). Knowledge of the modifiable risk factors contributing to NCDs presents an 
opportunity to find effective interventions to reduce the incidence of NCDs (4). A vast body of 
observational and experimental evidence has shown that people with healthier diets have a lower 
risk of developing NCDs. A meta-analysis of nine cohort studies (n=91,379 men and n=129,701 
women) reported that the risk of developing coronary heart disease decreased by 4% [RR (95%CI): 
0.96 (0.93–0.99), P<0.0027] for each additional portion per day of fruit and vegetable intake and 
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decreased by 7% [RR (95%CI): 0.93 (0.89–0.96), P<0.0001] for fruit intake (5). Vegetable intake also 
reduced the risk of mortality [RR (95%CI): 0.74 (0.75–0.84), P<0.0001] and fatal and nonfatal 
myocardial infarctions [RR (95%CI): 0.95(0.92–0.99),P<0.0058] (5). Another systematic review of 
randomised control trials found that reducing the consumption of dietary saturated fat reduced the 
risk of cardiovascular events by 17% [RR (95%CI) 0.83 (0.72 to 0.96)] in individuals regardless of 
whether they had a previous cardiovascular event or not (10).  The evidence from these and other 
studies demonstrates the potential for lifestyle interventions, including those addressing dietary 
risks, to prevent NCDs.  
In light of the above evidence and the need to adopt interventions that are effective in halting the 
rise in NCDs globally, and especially in LMICs, the WHO proposed a Global Action Plan for the 
prevention and control of NCDs (2). This action plan highlights the need to use strategies based on 
the latest scientific evidence and/or best practice, cost-effectiveness, affordability and public health 
principles, while ensuring that recommendations are culturally acceptable (2).  
 
Systematic reviews as sources of evidence and to identify research gaps 
The best available evidence is commonly considered to be from rigorously conducted and reported 
systematic reviews. Cochrane systematic reviews are regarded as high quality sources of synthesised 
scientific evidence, as they follow robust and standardised methodology (15). Cochrane systematic 
reviews attempt to collate all empirical evidence that fits pre-specified eligibility criteria in order to 
answer a specific research question (198). Studies that fit the inclusion criteria undergo an 
assessment of methodological quality to evaluate the extent to which bias was avoided. The 
characteristics and findings of the included studies are then synthesized, presented and reported 
with consideration of the methodological quality of included studies. Some systematic reviews 
include a meta-analysis; a process that uses statistical methods to combine the results of 
independent studies to provide more precise estimates of the effects of an intervention than those 
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derived from the individual studies (198). Meta-analyses also facilitate investigations of the 
consistency of evidence across studies and exploring  differences between studies (198). Cochrane 
nutrition reviews may thus serve as a source of high quality evidence to identify strategies that will 
help to prevent and control NCDs globally. 
In Cochrane reviews authors are required to include sections about the implications for practice and 
research in light of the evidence that has been synthesised in the review; information that is used 
increasingly often by people making decisions about future research (198). The “implications for 
research” section should include information about the need for further research, as well as the 
desirable nature of this research (199). Even though the extent to which this section is completed in 
Cochrane reviews is variable, most reviews identify residual uncertainty and are a rich source of 
suggestions for further research (17). Analysing the content of the “implications for research” 
section of Cochrane reviews can help inform primary research gaps in this area, as well as identify 
interventions for which the evidence is conclusive and thus do not require further research (18). The 
problem, however, is the variability in formulating and reporting research recommendations by 
different systematic review authors (19). 
The EPICOT+ framework was developed to provide a means of standardised reporting of 
recommendations under the “implications for research” section of reviews (20). According to the 
EPICOT+ framework, research recommendations should be made in consideration of the current 
state of evidence (E) found by a thorough up to date literature search, the number of systematic 
reviews and primary studies being analysed and the total number of the participants from the 
reviews. Other factors to consider when making recommendations include the population (P) being 
studied (type of participants, their age, race, gender, comorbidities and specific inclusion criteria), 
the intervention (I) being tested (type, dose, frequency, duration), the comparison (C) (placebo, 
other drugs or no intervention, duration), the outcome of interest (O) and the time stamp (T) (i.e. 
the date at which the recommendations are made). The “+” refers to the study design and the 
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burden of the disease of interest, which are additional elements to be considered and stated clearly 
when formulating recommendations. Apart from allowing for the formulation of recommendations 
in a standardised manner, using the EPICOT+ framework ensures that recommendations are specific 
and explicit and thus more useful (20). 
 
Internal Validity and reporting conflicts of interest in Cochrane Reviews 
For valid interpretation and application of systematic review findings, high methodological quality is 
a prerequisite. A Measurement Tool to Assess Systematic Reviews (AMSTAR) has been developed to 
assess the methodological quality of systematic reviews (200). The AMSTAR tool has been tested and 
shown to have good agreement, reliability, construct validity and feasibility compared to other tools 
that assess methodological quality, such as the Overview of Quality Assessment Questionnaire 
(OQAQ) and the Sacks' instrument (201). The AMSTAR tool aims to ensure that bias was avoided 
during the conduct of systematic reviews, through evaluating the methodology reported against 11 
distinct criteria (200). For each criterion on the checklist, a “Yes” is regarded as adequate, except for 
item 4 where the adequate answer is “No”. A score of one is assigned for each adequate response 
and the scores are added up to give a total that ranges from zero to a maximum of eleven. The 
quality of reviews is then graded according to their total score: low quality (0-4), moderate quality 
(5-8) and high quality (9-11) (202).  
 
According to the AMSTAR tool checklist, item 11 requires that conflicts of interest (COI) and sources 
of support be clearly acknowledged in both the systematic review and the primary studies included 
in the reviews (201). Conflict of interest is defined as a set of conditions in which professional 
judgment concerning a primary interest (such as a patient’s welfare or the validity of research) tends 
to be unduly influenced by a secondary interest (such as financial gain) (19). Most systematic review 
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authors report their COI and sources of funding for the review, however, a recent analysis found that 
only 21/296 (7%) reviewers reported the COI or funding sources of the primary studies included in 
their reviews (26). This has important implications since the outcome of the study and interpretation 
of study findings may be influenced by the source of funding and author-sponsor financial ties (22). 
A cross-sectional study explored the relationship between financial sponsorship and study 
conclusions on the benefits of milk, soft drinks and juice from interventional studies, observational 
studies, and scientific reviews (27).  None of the interventional studies that received industry 
funding reported unfavourable conclusions whilst 37% of the studies that did not receive industrial 
funding reported unfavourable conclusions about milk, soft drinks and juice consumption. Another 
study showed that studies reporting a favourable outcome were 7.61 times more likely to have 
received industry funding compared to the studies reporting an unfavourable outcome (21). A study 
of published systematic reviews assessing the effect of sugar-sweetened beverages (SSB) 
consumption and weight gain or obesity found that reviews which reported COI were five times 
more likely to present a conclusion of no positive association between SSB consumption and weight 
gain than reviews which did not report COI [RR (95%CI): 5.0 (1.3–19.3)] (29). These studies provide 
evidence that financial ties between study authors and funders may influence how authors interpret 
study findings. This highlights the need for review and primary study authors to declare COI and 
study sponsor information and affiliation when reporting studies. 
With the rise in NCDs globally, there is a need to identify research gaps in the primary evidence base 
on nutrition interventions that may be useful to control the NCD burden. Cochrane nutrition reviews 
on NCDs provide the best scientific evidence to inform further research; however, there is a need to 
explore how review authors report recommendations and identify areas that need improvement to 
achieve standardised and more useful reporting of recommendations. In this study, we aim to 
analyse the “implications for research” section of Cochrane nutrition reviews to identify gaps in 
primary evidence, to explore the reporting of COI, and to explore the association between financial 
COI and the findings of study in the primary studies included in these reviews. The aims of this 
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project are in line with the key objectives of the recently established Cochrane Nutrition field in 
South Africa. These objectives include examining the use of nutrition systematic reviews to inform 
the research agenda for new primary studies and systematic reviews, increasing the impact of 
Cochrane nutrition reviews across all stakeholders and enhancing the methodology of Cochrane 
nutrition reviews.  
 
2. Objectives 
1. To describe the reporting of the “implications for research” section of Cochrane nutrition reviews 
addressing NCDs according to the EPICOT+ framework 
2. To summarize current gaps in primary research based on the “implications for research” section of 
Cochrane nutrition reviews addressing NCDs 
3. To assess the reporting of COI and financial sponsors in included English primary studies of a 
random sample of Cochrane nutrition reviews addressing NCDs  
4. To explore the influence of author-sponsor financial ties and funding source on study outcomes 
and interpretation of the study outcomes in included English primary studies of a random sample of 
Cochrane nutrition reviews addressing NCDs 
 
For this project, we will only include reviews addressing the four major groups of NCDs, namely 
cardiovascular diseases, cancer, respiratory disease and diabetes and their nutrition-related risk 
factors (e.g. obesity). 
 
3. Methods 
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3.1 Study Design 
This will be a cross-sectional descriptive study analysing the implications for research section of 
Cochrane nutrition reviews addressing the four major groups of NCDs to identify knowledge gaps in 
the evidence base, and to assess the reporting of COI and funding sources in primary studies 
included in a sample of these reviews will be assessed.  
 
3.2 Data Source 
The source of systematic reviews for this study is a database of Cochrane nutrition reviews. This 
database was compiled for a previous project, in which all active records in the Cochrane Database 
of Systematic Reviews (n=8484) up to 31 July 2015 were screened to identify all nutrition reviews 
using a pre-specified definition. Nutrition reviews were defined as those that investigate the 
effectiveness of interventions of: 
(1) Diets and dietary patterns; foods; formulated, fortified or enriched foods or nutritional products 
and nutrients and bioactive non-nutrients naturally in foods delivered orally, enterally or 
parenterally; 
(2) Nutrition education, promotion, counselling and programmes; coordination of care or delivery of 
foods or nutrients; 
(3) Any policies, programmes or systems that influence outcomes clearly distinguishable as nutrition-
related (nutrition-sensitive).  
Screening of reviews using the above definition yielded a total of 470 eligible completed reviews. 
The methodological quality of all identified reviews has already been assessed using AMSTAR (200).  
 
3.3 Data collection and analysis 
Stellenbosch University  https://scholar.sun.ac.za
174 
 
3.3.1 Selection of Reviews 
Two researchers will independently screen the Cochrane nutrition reviews database (n=470) 
described above (section 3.2) by title, abstract and full-text to identify all eligible reviews. A review 
will be considered eligible if it addresses any of the four major groups of NCDs, i.e cardiovascular 
diseases, cancer, respiratory disease and diabetes or their nutrition-related risk factors (e.g. obesity). 
Any disagreement on inclusion or exclusion of reviews will be resolved by discussion with a third 
researcher. Reviews that do not fit the inclusion criteria will be excluded from the study. 
 
3.3.2 Selection of primary studies included in Cochrane nutrition reviews focussing on NCDs 
From the eligible Cochrane nutrition reviews selected in section 3.3.1, we will draw a random sample 
of reviews using an online random sequence generator www.random.org/sequences. The primary 
studies included in this sample will be accessed for the analysis on the reporting of COI and financial 
sponsors and on the association between study outcomes and author conclusions. For each review 
included in the random sample, we will extract the references of the included primary studies from 
the reference list of the reviews. We will search for the full-texts of these primary studies using the 
citation, the PubMed ID or the DOI, and download them. In instances where there is more than one 
reference for the same study in a review, the most recent reference of that study will be selected. 
Owing to limited resources, only articles published in English will be included in this analysis.  
 
3.3.3 Data Collection 
A pair of researchers will independently extract data from the included reviews using a standardized 
data extraction form (Addendum 1). This form will be piloted on 10 included reviews to evaluate its 
usability, completeness, and to identify any technical problems, and it will be adjusted accordingly. 
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Any discrepancies will be resolved by consensus and discussion with a third author if needed. The 
sections below outline the information that will be extracted from included reviews. 
 
Describing the reporting of the “implications for research” section of Cochrane nutrition reviews 
according to the EPICOT+ framework  
To inform the content analysis of the “implications for research” section we will extract the following 
EPICOT+ items for all reviews included in this study, as defined in section 3.3.1: participants, 
intervention, comparison, outcomes, time frame of the study and study design. If an EPICOT+ 
element is explicitly stated and explained in the recommendations, we will record a “Yes” and if the 
element is not stated in the implications for research section, we will record a “No” in Table 1 of the 
data extraction form (Addendum 1).  
 
Identifying current gaps in primary evidence based on the “implications for research” section of 
Cochrane nutrition reviews 
We will record a summary of a recommendation for each EPICOT+ element stated in the in the 
“implications for research section”. The summary of the recommendations for each EPICOT+ 
element represent the research gaps in the primary evidence base for the particular NCD being 
addressed in that review. 
 
Reporting of conflicts of interest and funding sources and exploring the influence of author-
sponsor financial ties and funding source on study outcomes and interpretation of the study 
outcomes in included English primary studies of a random sample of Cochrane nutrition reviews 
on NCDs 
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We will extract the following information from the full-texts of English primary studies included in 
the random sample of the reviews: title of study, NCD addressed, NCD group addressed, study 
design (randomised control trial, experimental non-randomized trials, observational studies). We will 
also categorise the studies according to whether COI was reported or not, type of funding sources 
(industry, non-industry, or both), funding source not disclosed or not reported, study not funded, 
author-sponsor financial ties disclosed, study findings and author conclusions (favourable to sponsor 
or unfavourable to sponsor).  
 
We will extract the online declaration of interest if it is stated that interests have been declared 
online. Author-financial ties will be defined as authors who are current/former industry consultants, 
current/former industry board members, current/former industry employees, receiving royalties, 
authors receiving travel reimbursement, have other relationships with industry, authors who hold 
patents (planned, pending, or issued) or authors who provide expert testimony. Information on 
author-sponsor financial ties will be extracted from statements in acknowledgements, potential 
conflict of interest statements and/or footnotes. Funding sources for the reviews will be extracted 
from the sources of support declaration or acknowledgments, and will be classified as industry, non-
industry (for example, public granting agency, private not-for-profit granting agency), combined 
(industry and non-industry), funding not reported, review not funded, review funding information 
not disclosed. A favourable outcome is where the study favoured the experimental item 
(intervention) over the existing standard of care, or otherwise arrived at a positive conclusion 
regarding the item being evaluated in favour of the sponsor. An unfavourable outcome is where the 
study favoured the existing standard of care or comparator item over the experimental item being 
evaluated and the conclusion supports the comparator over the intervention or when the item being 
studied has no superiority over the existing standard or comparator and is not in favour with the 
sponsor. 




3.4 Data Analysis 
Data will be analysed using STATA. We will use descriptive statistics and data will be presented as 
counts and percentages and visually as graphs and tables. 
 
Characteristics of included reviews and primary studies  
We will report the screening and selection of Cochrane nutrition reviews and included primary 
studies in form of a flow chart. The AMSTAR ratings will be tested for normality using Kolmogorov-
Smirnov test and if the data is normally distributed we will report the ratings as means and standard 
deviation, if the data is not normally distributed, we will report the median and inter-quartile ranges. 
We will report the online date and time stamped random sequence which will be used to select the 
random sample of reviews for the COI analysis. We will report study title, the counts and proportions 
of selected reviews according to NCD group (cardiovascular diseases, cancer, respiratory disease and 
diabetes). We will report the following characteristics in table form for primary studies included in 
the random sample of Cochrane nutrition reviews: Study title, population, NCD being addressed, 
NCD grouping (cardiovascular diseases, cancer, respiratory disease and diabetes), participants, 
intervention, comparison and outcome.  
 
Reporting of the “implications for research” according to EPICOT+ Framework 
We will report the number of reviews making recommendations according to the EPICOT+ 
framework elements: population, intervention, comparison, outcome and time frame of study 
overall and for each NCD being addressed. The data will be presented as counts and percentages in 
the form of bar graphs. For example, the total number of reviews that made recommendations 
considering the population will be expressed as a percentage of the total number of reviews 
Stellenbosch University  https://scholar.sun.ac.za
178 
 
included in the study. This will be done for each element of the EPICOT+ framework. We will also 
report the number of reviews that reported all the EPICOT+ framework elements as a percentage of 
the total number of reviews included in this study. We will give a description of which EPICOT+ 
framework elements are better or less well reported in the NCD reviews.  
 
Summarising research gaps in primary evidence base 
Firstly we will report the research gaps extracted from the implications for research section for each 
specific NCD and risk factors that fall within the 4 major groups (cardiovascular diseases, cancer, 
respiratory disease and diabetes), from the summaries of recommendations for each EPICOT+ 
element reported in the review section. We will highlight the participants, intervention, outcome, 
specific study design and length of time which further primary research should focus on. Secondly, 
we will report the “implications for research” data for each NCD according to the following 
categories: no more studies required, more studies required overall, more studies required with 
better quality, more studies required in different settings, more studies required in different 
populations, more studies with different interventions, more studies with different outcomes, more 
studies with longer follow up and further evidence unlikely to come from studies. We will give the 
counts and percentages of each category of “implications for research” according to the NCD being 
addressed. These data will be present in form of a graph and table. 
 
Influence of funding source and author financial affiliation on study outcomes in English included 
primary studies of the random sample of Cochrane nutrition reviews 
The data on the following characteristics of included primary studies will be presented as counts and 
percentages of the total number of included primary studies: reporting of conflict of interest ( e.g. 
number of studies that reported COI / total number of English included primary studies) , disclosure 
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of author-financial sponsor ties, number of authors with author-sponsor financial ties, type of study 
sponsor (industrial, non-industrial, both industrial and non –industrial), study sponsor not reported, 
study outcome and conclusion by authors (Favourable to sponsor and Unfavourable to sponsor). We 
will group the included primary studies according to the study outcome (Favourable outcome 
sponsor and unfavourable outcome to sponsor) and report the frequency of included primary 
studies that reported or did not report COI, disclosed author-sponsor affiliation ties and the 
frequency of each type of study sponsor (industrial, non-industrial, both industrial and non –
industrial) in form of a bar graph. To measure the association between the type of study sponsor and 
study outcome and author conclusions and the association between author-sponsor financial ties 
and study outcome and author conclusions, we will do multiple logistic regression analysis that will 
include potential predictors to estimate adjusted odds ratios. The model will include the following 
variables: conflict of interest, author-sponsor financial ties, type of study sponsor and study design.  
 
3.5 Ethical Considerations 
Since there will be no direct involvement of human or animal participants, there is no need to seek 
ethical approval for this study. 
3.6 Limitations 
The reviews considered in this study are from one source (Cochrane nutrition reviews) hence there 
might be a limited scope for nutrition and NCD topics covered. We only focussed on included studies 
that have been published in English only which poses a selection bias. 
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Stellenbosch University  https://scholar.sun.ac.za
180 
 
1.  WHO | Global Action Plan for the Prevention and Control of NCDs 2013-2020 [Internet]. 
WHO. [cited 2016 Jul 14]. Available from: http://www.who.int/nmh/events/ncd_action_plan/en/ 
2.  Terzic A, Waldman S. Chronic Diseases: The Emerging Pandemic. Clin Transl Sci. 2011 Jun 
1;4(3):225–6.  
3.  Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL, Comparative Risk Assessment 
Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 
Lond Engl. 2002 Nov 2;360(9343):1347–60.  
4.  Wang S, Marquez P, Langenbrunner J. Toward a healthy and harmonious life in China : 
stemming the rising tide of non-communicable diseases [Internet]. The World Bank; 2011 Jul [cited 
2016 Jul 21] p. 1–48. Report No.: 63426. Available from: 
http://documents.worldbank.org/curated/en/2011/07/14639951/toward-healthy-harmonious-life-
china-stemming-rising-tide-non-communicable-diseases 
5.  Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and Vegetable Consumption and Risk 
of Coronary Heart Disease: A Meta-Analysis of Cohort Studies. J Nutr. 2006 Jan 10;136(10):2588–93.  
6.  Hardy ML, Duvall K. Multivitamin/multimineral supplements for cancer prevention: 
implications for primary care practice. Postgrad Med. 2015 Jan 2;127(1):107–16.  
7.  Ye EQ, Chacko SA, Chou EL, Kugizaki M, Liu S. Greater Whole-Grain Intake Is Associated with 
Lower Risk of Type 2 Diabetes, Cardiovascular Disease, and Weight Gain. J Nutr. 2012 Jan 
7;142(7):1304–13.  
8.  Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for 
cardiovascular disease. In: Cochrane Database of Systematic Reviews [Internet]. John Wiley & Sons, 
Ltd; 2015 [cited 2016 Sep 26]. Available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011737/abstract 
Stellenbosch University  https://scholar.sun.ac.za
181 
 
9.  Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based 
medicine: what it is and what it isn’t. BMJ. 1996 Jan 13;312(7023):71–2.  
10.  Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2016 Aug 14]. 
Available from: http://handbook.cochrane.org/ 
11.  12 Interpreting results and drawing conclusions [Internet]. [cited 2016 Jul 22]. Available 
from: 
http://handbook.cochrane.org/chapter_12/12_interpreting_results_and_drawing_conclusions.htm 
12.  Clarke L, Clarke M, Clarke T. How useful are Cochrane reviews in identifying research needs? 
J Health Serv Res Policy. 2007 Apr;12(2):101–3.  
13.  Lavis JN, Posada FB, Haines A, Osei E. Use of research to inform public policymaking. Lancet 
Lond Engl. 2004 Nov 30;364(9445):1615–21.  
14.  Mbuagbaw L, Kredo T, Welch V, Mursleen S, Ross S, Zani B, et al. Critical EPICOT items were 
absent in Cochrane human immunodeficiency virus systematic reviews: a bibliometric analysis. J Clin 
Epidemiol. 2016 Jun;74:66–72.  
15.  Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al. How to 
formulate research recommendations. BMJ. 2006 Oct 14;333(7572):804–6.  
16.  Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of 
AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med 
Res Methodol. 2007 Feb 15;7:10.  
17.  Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a 
reliable and valid measurement tool to assess the methodological quality of systematic reviews. J 
Clin Epidemiol. 2009 Oct;62(10):1013–20.  
Stellenbosch University  https://scholar.sun.ac.za
182 
 
18.  Seo H-J, Kim KU. Quality assessment of systematic reviews or meta-analyses of nursing 
interventions conducted by Korean reviewers. BMC Med Res Methodol. 2012 Aug 28;12:129.  
19.  Petryna A. Ethical variability: Drug development and globalizing clinical trials. Am Ethnol. 
2005 May 1;32(2):183–97.  
20.  Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et al. Epidemiology and 
Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study. 
PLOS Med. 2016 May 24;13(5):e1002028.  
21.  Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig W-D, Lieb K. The financing of drug 
trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of 
the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch 
Ärztebl Int. 2010 Apr;107(16):279–85.  
22.  Lesser LI, Ebbeling CB, Goozner M, Wypij D, Ludwig DS. Relationship between Funding 
Source and Conclusion among Nutrition-Related Scientific Articles. PLOS Med. 2007 Jan 9;4(1):e5.  
23.  Bes-Rastrollo M, Schulze MB, Ruiz-Canela M, Martinez-Gonzalez MA. Financial Conflicts of 
Interest and Reporting Bias Regarding the Association between Sugar-Sweetened Beverages and 





6. Addendum  
1: Data Extraction form 
Stellenbosch University  https://scholar.sun.ac.za
183 
 




Table 1: Describing the reporting of “implication of research” according to the EPICOT+ 
framework. 
EPICOT Element   Summary of implications for 
research recommended 
Participants Yes No  
Intervention Yes No  
Comparison Yes No  
Outcomes Yes  No  
Time stamp Yes  No  
Study Design Yes No  
 
Table 2: Characteristics of English included primary studies of the randomly selected    sample of 
Cochrane nutrition reviews on NCDs. 
 
Title of Systematic Review 
 
Non communicable disease group 
 
Non Communicable Diseases  
 




Data domain Variables  
Study designs  Randomised controlled trials  
 parallel  
 cross-over design;  
 
 Experimental non-
randomised studies  
 non-randomised 
controlled trials, 
 controlled before-after 
studies,  
 interrupted time series  
 repeated measures 
studies 
 





Primary Study title  
NCD being addressed  
NCD group  
Number of authors  
Reporting of conflict of 
interest 
 Reported  
 Not reported  





 Not Disclosed  
Number of authors with 
author-sponsor ties 
 
Type of sponsor  industrial,   
 non-industrial,   
 both industrial and non –
industrial,  
 
 not reported  
Study outcome and conclusion 
by authors 
 Favourable to sponsor   
  Unfavourable to sponsor  
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Table of Data Extraction Domains  
 
Selection of Cochrane Nutrition Reviews 
Cochrane Review Accession Number 
Title of Cochrane Review 
Withdrawn Cochrane Review 
Complete Cochrane review 
Selection of Nutrition Reviews by SR 
Independent and duplicate selection of Nutrition reviews by CN and SD  
Cochrane Reviews addressing alternative nutrition supplements 
Cochrane Reviews addressing alternative nutrition supplements with included primary studies 
Number of included Primary Studies in Cochrane Reviews addressing alternative nutrition supplements 
 
EPICOT+ Framework analysis for Cochrane Reviews and Research Gaps analysis 
Cochrane Review Accession Number 
Title of Cochrane Nutrition Review 
Non-communicable diseases 
Non-communicable diseases grouping 
Risk Factor 
Brief description of Participants, interventions, comparison and outcomes being addressed in the review 
Evidence 
Description of Evidence (Implications for research section text) 
Population 
Description of Population (Implications for research section text) 
Intervention  
Description of Intervention (Implications for research section text) 
Comparison 
Description of Comparison (Implications for research section text) 
Outcome 
Description of Outcome (Implications for research section text) 
Last date of literature search 
Study Design 
Description of Study Design (Implications for research section text) 
Burden of disease  
Description of burden of disease  (Implications for research section text) 
Timeliness (Length of study follow up or duration of study) 
Description of Timeliness  (Implications for research section text) 
 
Implications for Research analysis for Cochrane Reviews 
No more trials required 
More Cohort studies required 
More Qualitative Studies required 
Stellenbosch University  https://scholar.sun.ac.za
186 
 
Further evidence most likely not to come from trials 
More Systematic Reviews required 
More Cost effective and Economic Evaluation studies required 
More trials with different comparison required 
More long term trials required 
More trials with longer duration of follow up required 
More trials with larger sample size required 
More trials with better quality required 
More trials in a different population required 
More trials with different interventions required 
More trials with different outcomes required 
More RCTs required overall 
 
Reporting of Conflict of interest, study financial sponsors and author financial ties and the influence of 
funding source on study outcome and authors conclusions in included primary studies 
Primary study title 
Primary study Journal published 
Cochrane Review Accession Number (parent Cochrane nutrition review) 
Cochrane review title 
Non-communicable disease being addressed 
Nutrition-related risk factors 





Study Design of primary study 
Country where primary study was conducted 
Disclosure of financial sponsor 
Role of Financial sponsor mentioned 
Name of financial sponsor 
Food Industry sponsor 
Governmental sponsor 
Non Profit sponsor 
Big Pharma (Pharmaceutical industry) sponsor 
Other for profit entities sponsor  
Mixedfundingsources1(with Food Industry) 
Mixed funding sources 2 (with Big Pharma) 
Mixed funding sources3 (with food industry and Big Pharma) 
Mixed funding sources 4 (without industry) 
Outcome favourable to Sponsor 
Outcome favourable to sponsor justification 
Conflict of interest disclosure 




Current or former industry employee 
Current or former industry consultant 
Industry grants 
Non Industry grants 
Payment for lectures 
Payment for manuscript preparation 
Patents (received or yet to be received) 
Royalties 




Author-financial sponsor ties  disclosed 
Name of Author –financial sponsor ties 
Outcome favourable to author-financial sponsor ties 
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